

Hospital register

Hospital-based Cancer Registry

Oncology Institute Ljubljana

of the Institute of Oncology Įjubljana

Annual Report

annual report

Report

Report of

Hospital register

Oncology Institute Ljubljana

the Hospital-Based Cancer Registry

of the Institute of Oncology Ljubljana

2022

Title *Title*

Ljubljana Oncology Institute Hospital Registry Report 2022

Report of the Hospital-Based Cancer Registry of the Institute of Oncology Ljubljana 2022

Editorial Board *Editorial Board*

Vesna Zadnik, editor-in-chief Katarina Lokar

Sonja Tomšič Tina Žagar

*Data Processing* and *Analysis*

Katarina Lokar Miran Mlakar Tina Žagar Nika Bric Maja Jurtela

Design and Typesetting *Design and Typesetting*

Nika Bric

Reading *Copy Editing*

Jezikovna zadruga Soglasnik / Soglasnik Language Cooperative

Printing *Printing*

Media Bus d.o.o., Domžale

Publisher *Published by*

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia

Cancer Epidemiology and Cancer Registry Sector Cancer Registry of the Republic of Slovenia / Slovenian Cancer Registry

Print run *Published in*

50 copies

Citation advice *Recommended Reference*

Report of the Oncology Institute of Ljubljana Hospital Registry 2022. Ljubljana: Oncology Institute of Ljubljana, Oncology Epidemiology and Cancer Registry, Cancer Registry of the Republic of Slovenia, 2023.

Report of the Hospital-Based Cancer Registry of the Institute of Oncology Ljubljana 2022. Ljubljana: Institute of Oncology Ljubljana, Cancer Epidemiology and Cancer Registry Sector, Slovenian Cancer Registry, 2023.

Staff of the Ljubljana Oncology Institute Hospital Registry

*Staff of the Hospital-based Cancer Registry of the Institute of Oncology Ljubljana*

Agata Čampa Maruška Ferjančič Martina Omerzo

Staff of the Slovenian Cancer Registry *Staff of the Slovenian Cancer Registry that also contributed* Andrej Krašovec

Frančiška Škrlec Branka Pestotnik Laura Šeneker Zupanc Polona Škulj

Urška Tomšič Boštjan Zavratnik Brigita Zore Vesna Drolec Katja Hribar

Katja Kolenc Mokotar Polona Rus

Snežana Umičević Sabina Prvinšek

Contact *Correspondence to*

Register raka Republike Slovenije / Slovenian Cancer Registry Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenia

Telephone + 386 1 5879 450 E-mail: [register@onko-i.si](mailto:register@onko-i.si) Website:

<http://www.onko-i.si/rrs/br> [http://www.slora.si/ http://www.onko-i.si/eng/crs/hr](http://www.onko-i.si/eng/crs/hr) <http://www.slora.si/en/>

4

Table of contents

*Contents*

Editorial 6

Editorial 7

Data sources and registration methods 8

Data Sources and Registration Methods 9

Geographical distribution of patient inflows 10

Cancer treatment trends over time 12

Incidence by multidisciplinary team 13

[Head and Neck Cancers / Head and Neck Cancers 14](#_TOC_250008)

[Gastrointestinal cancers / Gastrointestinal Cancers 15](#_TOC_250007)

[Thoracic Cancers / Thoracic Cancers 16](#_TOC_250006)

[Breast cancer, thyroid cancer and melanoma of the skin](#_TOC_250005)

[Breast Cancer, Thyroid Cancer and Skin Melanoma 17](#_TOC_250004)

[Gynaecological cancers / Gynaecological Cancers 19](#_TOC_250003)

[Urological Cancers / Urological Cancers 20](#_TOC_250002)

[Central Nervous System Tumours / Central Nervous System Tumours 21](#_TOC_250001)

[Soft Tissue and Bone Tumours 22](#_TOC_250000)

Malignant neoplasms of lymphoid, haematopoietic and related tissues

Malignant neoplasms of lymphoid, haematopoietic and related tissue 23

Distribution of cancers by sex and age 24

Incidence 25

Table 12:Cancer incidence by location, sex and age, OI Ljubljana 2022. 25

Table 12: Cancer incidence by site, sex and age, OI Ljubljana 2022. 25

Table 13: Incidence of microscopically (histologically and cytologically) confirmed

cancer cases by morphological type, OI Ljubljana 2022 29

Table 13: Incidence of microscopically (histologically and cytologically)

confirmed cancer cases by morphological type, OI Ljubljana 2022 29

Table 14: Incidence of non-Hodgkin lymphomas (NHL) by location,

OI Ljubljana 2022. 33

Table 14: Incidence of non-Hodgkin lymphomas (NHL) by site,

OI Ljubljana 2022. 33

*Hospital registry of the Ljubljana General Hospital*

Treatment 36

|  |  |  |
| --- | --- | --- |
| Table 15: | Cancer incidence by stage, OI Ljubljana 2022. ........................................................... | 34 |
| Table 15: | Cancer incidence by stage, OI Ljubljana 2022. ........................................................ | 34 |

Table 16a: Number and proportions of operations, systemic treatments and radiation treatments by

locations of patients admitted for the first time to the Ljubljana ICU in 2022 36

Table 16a: Number and proportions of surgeries, systemic treatments andradiotherapy by site for patients first admitted to the OI Ljubljana

in 2022. 36

Table 16b: Number and proportions of surgeries, systemic treatments and radiation treatments by location in the first treatment in patients at the Ljubljana ICU,

first adopted in 2022 37

Table 16b: Number and proportions of surgeries, systemic treatments andradiotherapies by site as part of the first treatment at the OI

Ljubljana for patients admitted for the first time in 2022 37

*Hospital registry of the Ljubljana General Hospital*

5

Editorial

As early as 1938, when the Oncological Institute of Ljubljana (OI Ljubljana) was founded, the Medical Records and Statistics Service was established in a separate work unit to collect data on cancer patients, in addition to other statistics for the Institute's clinical research needs. When the National Population Cancer Registry was established at the Ljubljana Institute of Medicine in 1950, the Statistical Service also took over all the tasks related to the legally obligatory reporting to the Cancer Registry of the Republic of Slovenia. The Hospital Registry (BR) of the Ljubljana OPD was established, which today operates in the Oncological Epidemiology and Cancer Registry Division and collects and transmits to the National Registry data on patients who come to the Ljubljana OPD for diagnosis and treatment. As a result, the Ljubljana OPD is the only hospital in the country that employs specially trained nurses for the statutory reporting to the National Cancer Registry and does not leave the coding of the data to the National Cancer Registry. Complete and high quality data on patients treated at the Ljubljana OPD are thus available to the National Cancer Registry for about half of all cancer patients in Slovenia, and BR contributes to the National Cancer Registry one third of all reports (about 6,500 per year).

The data collected in the BR are also valuable for the Institute's professional and research work. They are the starting point for most of the clinical and epidemiological research carried out at the OI Ljubljana. They are also crucial for the preparation of reports on the number and type of diagnostic and medical interventions performed at the Ljubljana OPD, which are monitored by the National Cancer Control Programme. Following the example of the reports of the Cancer Registry of the Republic of Slovenia, the processed BR data are published annually in the form of standardised displays. The standardised report on the number and characteristics of patients, type of disease, and diagnostic and treatment modalities treated at the Ljubljana OPD in a given year informs the management, physicians and other professional staff of the Ljubljana OPD about the data processed in the BR.

This report presents data for 2022. We have added to the tables graphical displays of changes in the core indicators over the last ten years for the Institute as a whole, as well as broken down by the 11 multi-disciplinary expert teams. This report shows time trends for the period 2013 and 2018 to 2022. We have enriched the report by presenting data for the period 2016-2020 by selected cancer sites and statistical regions on the proportion of Slovenian cancer patients coming to the Ljubljana ICU for treatment. The latter analysis is only possible until 2020, as the Cancer Registry processes and reports data at a population level with a longer delay than the BR OI Ljubljana.

*Editorial*

Upon the establishment of the Institute of Oncology Ljubljana (OI Ljubljana) in 1938, a separate unit Health Records and Statistics Service was formed to collect cancer patient data in addition to other statistics for the Institute's clinical research needs. When the national population-based Slovenian Cancer Registry was established at the Institute in 1950, the unit also undertook all the tasks of the OI Ljubljana related to the mandatory reporting to the Slovenian Cancer Registry. The Hospital-Based Cancer Registry of the OI Ljubljana (HR) was established, which today operates within the Cancer Epidemiology and Cancer Registry sector, collecting the data on patients visiting the OI Ljubljana for diagnosis and treatment and transmitting them to the national Registry. The OI Ljubljana is therefore the only hospital in the country that employs specially trained nurses for the mandatory reporting to the national Registry and does not rely on the national Registry to code the data. Complete and high-quality data on patients seen at the OI Ljubljana are thus available to the national Registry for approximately half of all cancer patients in Slovenia, and the HR contributes one third of all cancer notifications to the national Registry (about 6,500 per year).

The data collected in the HR are also invaluable for the Institute's professional and research work. It forms the basis for most of the clinical and epidemiological research carried out at the OI Ljubljana. The data is also crucial for preparing reviews on the number and type of diagnostic and treatment interventions performed at the OI Ljubljana, which are monitored by the National Cancer Control Programme. Following the example of the Slovenian Cancer Registry reports, we annually publish the processed HR data in the form of standardised presentations. The standardised report on the number and characteristics of patients, the type of disease, and the diagnostic and treatment procedures received at the OI Ljubljana in a given year informs the decision ma- kers, physicians and other professional associates of the OI Ljubljana about the data processed in the HR.

This report presents data for 2022. The tables are accompanied by graphical representations of changes in key indicators over the last ten years for the OI Ljubljana as a whole, as well as broken down by eleven multidisciplinary specialist teams. This report presents time trends for the period from 2013 or 2018 to 2022. We have also enriched the report with data for the period 2016-2020 on selected cancer sites and statistical regions, indicating the percentage of Slovenian cancer patients coming to the OI Ljubljana for treatment. This analysis is only possible up to 2020, as the Cancer Registry processes and reports population-level data with a greater delay than the OI Ljubljana HR.

Data sources and registration methods

The primary source of data on disease and treatment is the treatment records, which are available in the Ljubljana OI information system - WebDoctor/Clinical. Based on the lists of new patients treated at the Ljubljana OPD, the BR's graduate nurses with specialised skills (coders) review their records and enter the data into the joint information system of the Hospital and Cancer Registry of the Republic of Slovenia. They record information on the type of disease (anatomical site of cancer, histological or cytological diagnosis, stage) and the type of treatment. The information system used by BR is directly linked to the Central Population Register by means of a specially secured web-based technology, where all the patient's personal data are checked, which is important for ensuring the quality of the data (e.g. that patients are not duplicated in the system), as well as the permanent address at the time of the diagnosis of the disease, and the patient's vital status is also updated on a daily basis.

The incidence of BR for each year includes all patients treated at the Ljubljana OPD - contrary to the rules of the national Cancer Registry, it also includes foreigners who do not have permanent residence in Slovenia. The definition of incidence also differs from the national one in the hospital register - the incidence year is the year in which the patient was first admitted to the Ljubljana OPD for a given disease, regardless of when the cancer was detected. The incidence rate of the Ljubljana ICU does not include readmissions to the Ljubljana ICU for progressions, recurrences and new primary cancers of the same organ of the same site, if the histological type of both cancers, e.g. left and right breast, was the same. Similarly, a new occurrence of cancer of the same histological type in the same organ, e.g. multiple lesions in the colon, is not counted in the incidence. We define the disease on the basis of the findings of any recorded investigation, from the operative census to the autopsy, if the patient has not previously been treated. In the case of multiple investigations, we choose the most reliable one.

Data from the medical records are transferred to the Registry's information system in a structured format, coded in accordance with international and National Cancer Registry rules. The 10th revision of the International Classification of Diseases and Related Health Problems for Statistical Purposes (ICD-10) has been in force since 1997 for the classification of neoplasms according to primary site. For the classification of neoplasms as malignant diseases, it is also important to note the classification of the morphology of neoplasms, for which we use the morphological part of the International Classification of Diseases for Oncology, third edition (ICD-O-3), updated for the second time since 2020.

To show the distribution of disease by stage at diagnosis in the annual reports, we use a simplified classification into one of three groups: limited disease, regionally widespread disease and distantly widespread disease. The simplified staging of solid tumours generally follows the TNM classification. Malignant lymphomas are defined according to the Ann-Arbor classification, FIGO stage is recorded for gynaecological cancers, and Clark depth of invasion and Breslow thickness are recorded for patients with malignant melanoma.

In the figures and tables showing treatments, only treatments that were performed at the Ljubljana OPD are taken into account. Only one treatment of the same type for each disease is counted. If a disease has been treated with several different treatments (e.g. surgery and radiotherapy), each treatment is counted separately; the sum of all treatments is therefore greater than the total diseases treated.

*Data Sources and Registration Methods*

The primary source of data on diseases and treatments are the patient records available in the OI Ljubljana information system WebDoctor/Clinical. Based on the lists of new patients treated by the OI Ljubljana, the nurses with specialised knowledge (coders) employed at the HR, routinely review the medical records and enter the data into the shared information system of the HR and national Registry. They record information on the type of disease (anatomical site of cancer, his- tological or cytological diagnosis, stage) and the type of treatment. The information system used by the HR is directly connected to the Central Population Registry through a specially secured web technology, where all the patient's personal data is verified, which is important to ensure data quality (e.g. to ensure that patients are not duplicated in the system), as well as daily upda- ting the changes in patients' permanent address and vital status.

In the HR, the incidence of each year includes all patients seen at the OI Ljubljana - in contrast to the rules of the national Registry, foreigners without permanent residence in Slovenia are also included. The definition of incidence also differs from that of the national Registry - the incidence year is the year in which the patient was first admitted to the OI Ljubljana for a given disease, regardless of when the cancer was first diagnosed. The incidence of OI Ljubljana does not include readmissions to OI Ljubljana for progression, recurrence and new primary cancer at the same site in the paired organs, if the histological type of both cancers, e.g. left and right breast, was the same. Similarly, a new occurrence of cancer of the same histological type in the same organ,

e.g. multiple lesions in the colon, is not counted in the hospital incidence. The disease is defined on the basis of the findings of any recorded procedure - from surgery to autopsy record, if the patient has not received treatment beforehand. In the case of multiple procedures, we select the most reliable one.

The data from the medical records are transferred to the Registry's information system in a structured format, coded in accordance with the international and national rules for cancer registries. For the classification of neoplasms by primary site, the 10th revision of the International Classifi- cation of Diseases and Related Health Problems for Statistical Purposes (ICD-10) has been in force since 1997. When classifying malignant diseases, it is also important to mention the classification of the morphology of neoplasms, for which we use the morphology axis of the International Classification of Diseases for Oncology, since 2020 its third edition (ICD-O-3), second update.




To present the distribution of disease by stage at diagnosis in the annual reports, we use a simplified classification into three groups: localised, regional and distant stage of disease. For solid tumours, the simplified stage definition generally follows the TNM classification. Malignant lymphomas are staged using the Ann Arbor classification, gynaecological cancers using the FIGO staging, and malignant melanomas according to Clark's level and Breslow's thickness.

In the figures and tables showing the treatments, only treatments performed at the OI Ljubljana are counted. Only one treatment of the same type is counted for each disease. If a disease was treated with several different treatments (e.g. surgery and radiotherapy), each treatment is counted separately; the sum of all treatments is therefore greater than the sum of all diseases treated.




Geographical distribution of patient inflows


*Geographical distribution of patient inflow*




Mouth and pharynx Mouth and pharynx




Colon Colon



Gallbladder and biliary tract Gallbladder and biliary tract




Trachea, bronchus and lung




Connective and soft tissue Connective and soft tissue


Oesophagus




Rectum and rectosigmoid junction Rectum and rectosigmoid junction



Pancreas Pancreas




Malignant melanoma of the skin Malignant melanoma of the skin




Breastfeeding Breast


Stomach Stomach




Liver and intrahepatic bile ducts Liver and intrahepatic bile ducts



Larynx throat




Other malignant neoplasms of the skin Skin, excl. melanoma




Cervix cervix uteri

Figure 1: Inflow of patients to the Ljubljana OPD (proportion of the average annual incidence rates in the Slovenian population 2016-2020) by selected cancer sites and statistical regions of residence (left and bottom).

Figure 1: Inflow of patients to OI Ljubljana (proportion of average annual incidence values in Slovenian population 2016-2020) by selected cancer sites and statistical regions of patients' residence (left and below).



All sites

0 %



Corpus uteri

25 %




50 %




75 %






Ovary Ovary

100 %







Prostate Prostate

Modo Testis




Central and autonomic nervous system Central and autonomic nervous system




Non-Hodgkin's lymphomas Non-Hodgkin's lymphomas

Kidney with renal pelvis Kindey with renal pelvis




Thyroid Thyroid gland



Diffuse plasmacytoma and malignant neoplasms of plasmacytes

Multiple myeloma and malignant plasma cell neoplasms

Bladder Bladder



Hodgkin's lymphoma Hodgkin's lymphoma



Leukaemias Leukaemias

Cancer treatment trends over time

*Time Trends in Cancer Treatment*

8000

7000



6000

Number / Number

5000

4000

3000

2000

1000

0

2013 2014 2015

2016

2017

Year

2018 2019 2020 2021

2022

Operated\* / By surgery\* Treated with systemic therapy / By systemic therapy

\*Curative and palliative surgery

Obsevani / By radiotherapy

 New cases / New cases

Figure 2: Number ofsurgeries, systemic treatments and radiation treatments in patients admitted for the first time to the Ljubljana OPD in the period 2013-2022.

Figure 2: Number of surgeries, systemic therapies and radiotherapies in patients admitted for the first time to the OI Ljubljana in the period 2013-2022.

60



50

40

30



%

20

10

0

2013 2014 2015

2016

2017

2018 2019 2020 2021

Year

2022

Operated\* / By surgery\* Treated with systemic therapy / By systemic therapy

\*Curative and palliative surgery

Obsevani / By radiotherapy

Figure 3: Proportion ofsurgeries, systemic treatments and radiotherapy in patients admitted for the first time to the Ljubljana OPD in the period 2013-2022.

Figure 3: Proportion of surgeries, systemic treatments and radiotherapies in patients admitted for the first time to the OI Ljubljana in the period 2013-2022.

Incidence by multidisciplinary team

*Incidence by Multidisciplinary Teams*

8000

7000

6000

5000

Number / Number

4000

3000

2000

All sites All sites



1000

800

Year

600

400

200

0

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

1200

1400

Year

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

0

1000

Urological cancers (C60-C68) Urological cancers

Thyroid cancer (C73) Thyroid cancer

Gastrointestinal cancers (C15-C26) Gastrointestinal cancers

CNS tumours (C71-C72) CNS tumours

Gynaecological cancers (C51-C58) Gynaecological cancers

Breast cancer (C50) Breast cancer

Cutaneous melanoma (C43) Skin melanoma

Soft tissue and bone tumours (C40-C41, C46-C49) Soft tissue and bone tumours

Thoracic cancers (C33-C34, C37-C38, C45.0) Thoracic cancers

Head and neck cancers (C00-C14, C30-C32, C69) Head and neck cancers

Malig. neoplas. of lymphoid, haematopoietic and related tissue (C81-C85, C90-C96) Malig. neoplas. of lymphoid, haematopoietic and related tissue

Number / Number

Figure 4: Incidence of selected cancer groups for the period 2013-2022, OI Ljubljana.

Figure 4: Incidence of selected cancer groups for the period 2013-2022, OI Ljubljana.

# Head and Neck Cancers / Head and Neck Cancers

160

140



120

100

Number / Number

80

60

40

20

0

2013 2014 2015 2016

2017

2018

Year

2019 2020 2021 2022

Oropharynx (C01, C05, C09, C10) Oropharynx

Larynx (C32) Larynx

Oral cavity (C02-C04, C06) Oral cavity

Lower pharynx (C12-C13) Hypopharynx

Other (C00, C07, C08, C11, C14, C30, C31, C69)

Other

Figure 5: Incidence of head and neck cancers 2013-2022, OI Ljubljana.

Figure 5: Incidence of head and neck cancers in the period 2013-2022, OI Ljubljana.

Table 1: Incidence ofhead and neck cancers by age, stage and treatment 2018-2022, OI Ljubljana. Table 1: Incidence of head and neck cancers by age, stage and treatment in the period 2018-2022,

OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C00-C14, C30-C32, C69) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 396 | 100,0 | 368 | 100,0 | 388 | 100,0 | 399 | 100,0 | 386 | 100,0 | 1937 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 1 | 0,3 | 1 | 0,3 | 2 | 0,5 | 1 | 0,3 | 1 | 0,3 | 6 | 0,3 |
| 20-49 | 37 | 9,3 | 37 | 10,1 | 33 | 8,5 | 32 | 8,0 | 30 | 7,8 | 169 | 8,7 |
| 50-74 | 294 | 74,2 | 284 | 77,2 | 301 | 77,6 | 306 | 76,7 | 291 | 75,4 | 1476 | 76,2 |
| 75+ | 64 | 16,2 | 46 | 12,5 | 52 | 13,4 | 60 | 15,0 | 64 | 16,6 | 286 | 14,8 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 104 | 26,3 | 105 | 28,5 | 109 | 28,1 | 111 | 27,8 | 99 | 25,6 | 528 | 27,3 |
| Extended / Regional | 281 | 71,0 | 251 | 68,2 | 264 | 68,0 | 267 | 66,9 | 272 | 70,5 | 1335 | 68,9 |
| Razsejan / Distant | 9 | 2,3 | 12 | 3,3 | 15 | 3,9 | 17 | 4,3 | 14 | 3,6 | 67 | 3,5 |
| Neznan / Unknown | 2 | 0,5 | 0 | 0,0 | 0 | 0,0 | 4 | 1,0 | 1 | 0,3 | 7 | 0,4 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 363 | 91,7 | 342 | 92,9 | 357 | 92,0 | 363 | 91,0 | 360 | 93,3 | 1785 | 92,2 |
| Operirani\*\* / By surgery\*\* | 4 | 1,0 | 1 | 0,3 | 3 | 0,8 | 0 | 0,0 | 0 | 0,0 | 8 | 0,4 |
| Treated with systemic therapy  By systemic therapy | 40 | 10,1 | 53 | 14,4 | 39 | 10,1 | 34 | 8,5 | 34 | 8,8 | 200 | 10,3 |
| Obsevani / By radiotherapy | 352 | 88,9 | 330 | 89,7 | 341 | 87,9 | 347 | 87,0 | 350 | 90,7 | 1720 | 88,8 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Gastrointestinal cancers / Gastrointestinal Cancers

450

400

350



300

Number / Number

250

200



150

100

50

0

2013 2014 2015 2016

2017

2018

Year

2019 2020 2021 2022

Oesophagus (C15) Oesophagus

Pancreas (C25) Pancreas

Danka (C19-C20)

Rectum

Other (C17, C21, C26)

Other

Stomach (C16) Stomach

Large intestine (C18) Colon

Liver, gallbladder and bile ducts (C22-C24) Liver, gallbladder and bile ducts

Figure 6: Incidence of gastrointestinal cancers 2013-2022, OI Ljubljana.

Figure 6: Incidence of gastrointestinal cancers in the period 2013-2022, OI Ljubljana.

Table 2: Incidence ofgastrointestinal cancers by age, stage and treatment 2018-2022, OI Ljubljana. Table 2: Incidence of gastrointestinal cancers by age, stage and treatment in the period 2018-2022, OI Ljubljana

Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C15-C26) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 965 | 100,0 | 953 | 100,0 | 943 | 100,0 | 998 | 100,0 | 943 | 100,0 | 4802 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 1 | 0,1 | 0 | 0,0 | 2 | 0,2 | 3 | 0,3 | 5 | 0,5 | 11 | 0,2 |
| 20-49 | 96 | 9,9 | 103 | 10,8 | 109 | 11,6 | 106 | 10,6 | 105 | 11,1 | 519 | 10,8 |
| 50-74 | 657 | 68,1 | 652 | 68,4 | 637 | 67,6 | 685 | 68,6 | 637 | 67,6 | 3268 | 68,1 |
| 75+ | 211 | 21,9 | 198 | 20,8 | 195 | 20,7 | 204 | 20,4 | 196 | 20,8 | 1004 | 20,9 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 83 | 8,6 | 95 | 10,0 | 103 | 10,9 | 126 | 12,6 | 120 | 12,7 | 527 | 11,0 |
| Extended / Regional | 581 | 60,2 | 538 | 56,5 | 541 | 57,4 | 542 | 54,3 | 495 | 52,5 | 2697 | 56,2 |
| Razsejan / Distant | 285 | 29,5 | 317 | 33,3 | 296 | 31,4 | 318 | 31,9 | 326 | 34,6 | 1542 | 32,1 |
| Neznan / Unknown | 16 | 1,7 | 3 | 0,3 | 3 | 0,3 | 12 | 1,2 | 2 | 0,2 | 36 | 0,7 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 752 | 77,9 | 714 | 74,9 | 721 | 76,5 | 717 | 71,8 | 669 | 70,9 | 3573 | 74,4 |
| Operirani\*\* / By surgery\*\* | 157 | 16,3 | 173 | 18,2 | 196 | 20,8 | 196 | 19,6 | 167 | 17,7 | 889 | 18,5 |
| Treated with systemic therapy  By systemic therapy | 525 | 54,4 | 490 | 51,4 | 475 | 50,4 | 437 | 43,8 | 430 | 45,6 | 2357 | 49,1 |
| Obsevani / By radiotherapy | 407 | 42,2 | 350 | 36,7 | 323 | 34,3 | 312 | 31,3 | 288 | 30,5 | 1680 | 35,0 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Thoracic Cancers / Thoracic Cancers

1000

900



800

700

Number / Number

600

500

400

300

200

100

0

2013 2014 2015 2016



2017

Year

2018

2019 2020 2021 2022

Lung (C33-C34) Lung

Mesothelioma of pleura (C45.0) Mesothelioma of pleura

Other (C37-C38)

Other

Figure 7: Incidence ofthoracic cancers 2013-2022, OI Ljubljana. Figure 7: Incidence of thoracic cancers in the period 2013-2022, OI Ljubljana.

Table 3: Incidence ofthoracic cancers by age, stage and treatment in 2018-2022, OI Ljubljana.

Table 3: Incidence of thoracic cancers by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C33-C34, C37-C38, C45.0) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 835 | 100,0 | 769 | 100,0 | 772 | 100,0 | 787 | 100,0 | 827 | 100,0 | 3990 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 4 | 0,5 | 1 | 0,1 | 1 | 0,1 | 2 | 0,3 | 1 | 0,1 | 9 | 0,2 |
| 20-49 | 27 | 3,2 | 29 | 3,8 | 23 | 3,0 | 22 | 2,8 | 17 | 2,1 | 118 | 3,0 |
| 50-74 | 603 | 72,2 | 576 | 74,9 | 575 | 74,5 | 594 | 75,5 | 594 | 71,8 | 2942 | 73,7 |
| 75+ | 176 | 21,1 | 140 | 18,2 | 163 | 21,1 | 147 | 18,7 | 195 | 23,6 | 821 | 20,6 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 114 | 13,7 | 101 | 13,1 | 114 | 14,8 | 147 | 18,7 | 157 | 19,0 | 633 | 15,9 |
| Extended / Regional | 351 | 42,0 | 311 | 40,4 | 288 | 37,3 | 270 | 34,3 | 276 | 33,4 | 1496 | 37,5 |
| Razsejan / Distant | 369 | 44,2 | 355 | 46,2 | 370 | 47,9 | 369 | 46,9 | 393 | 47,5 | 1856 | 46,5 |
| Neznan / Unknown | 1 | 0,1 | 2 | 0,3 | 0 | 0,0 | 1 | 0,1 | 1 | 0,1 | 5 | 0,1 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 711 | 85,1 | 645 | 83,9 | 660 | 85,5 | 668 | 84,9 | 701 | 84,8 | 3385 | 84,8 |
| Operirani\*\* / By surgery\*\* | 4 | 0,5 | 3 | 0,4 | 1 | 0,1 | 0 | 0,0 | 2 | 0,2 | 10 | 0,3 |
| Treated with systemic therapy  By systemic therapy | 309 | 37,0 | 278 | 36,2 | 264 | 34,2 | 283 | 36,0 | 271 | 32,8 | 1405 | 35,2 |
| Obsevani / By radiotherapy | 635 | 76,0 | 569 | 74,0 | 575 | 74,5 | 572 | 72,7 | 616 | 74,5 | 2967 | 74,4 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Breast, thyroid and skin cancer melanoma

# Breast Cancer, Thyroid Cancer and Skin Melanoma

1400

1200



1000

800

Number / Number

600

400



200



0

2013 2014 2015 2016

2017

Year

2018

2019 2020 2021 2022

Breastfeeding (C50) Breast

Thyroid gland (C73) Thyroid gland

Cutaneous melanoma (C43) Skin melanoma

Figure 8: Incidence of breast cancer, thyroid cancer and melanoma of the skin in the period 2013-2022, OI Ljubljana.

Figure 8: Incidence of breast and thyroid cancer and skin melanoma in the period 2013-2022, OI Ljubljana.

*Breastfeeding Breast*

Table 4: Incidence of breast cancer by age, stage and treatment 2018-2022, OI Ljubljana.Table 4: Incidence of breast cancer by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C50) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 1230 | 100,0 | 1218 | 100,0 | 1071 | 100,0 | 1121 | 100,0 | 1079 | 100,0 | 5719 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| 20-49 | 239 | 19,4 | 226 | 18,6 | 275 | 25,7 | 270 | 24,1 | 250 | 23,2 | 1260 | 22,0 |
| 50-74 | 759 | 61,7 | 772 | 63,4 | 598 | 55,8 | 617 | 55,0 | 600 | 55,6 | 3346 | 58,5 |
| 75+ | 232 | 18,9 | 220 | 18,1 | 198 | 18,5 | 234 | 20,9 | 229 | 21,2 | 1113 | 19,5 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 711 | 57,8 | 704 | 57,8 | 639 | 59,7 | 649 | 57,9 | 648 | 60,1 | 3351 | 58,6 |
| Extended / Regional | 430 | 35,0 | 428 | 35,1 | 361 | 33,7 | 392 | 35,0 | 346 | 32,1 | 1957 | 34,2 |
| Razsejan / Distant | 88 | 7,2 | 84 | 6,9 | 70 | 6,5 | 80 | 7,1 | 84 | 7,8 | 406 | 7,1 |
| Neznan / Unknown | 1 | 0,1 | 2 | 0,2 | 1 | 0,1 | 0 | 0,0 | 1 | 0,1 | 5 | 0,1 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 1189 | 96,7 | 1172 | 96,2 | 1035 | 96,6 | 1079 | 96,3 | 1040 | 96,4 | 5515 | 96,4 |
| Operirani\*\* / By surgery\*\* | 962 | 78,2 | 965 | 79,2 | 841 | 78,5 | 840 | 74,9 | 824 | 76,4 | 4432 | 77,5 |
| Treated with systemic therapy  By systemic therapy | 950 | 77,2 | 1020 | 83,7 | 907 | 84,7 | 939 | 83,8 | 895 | 82,9 | 4711 | 82,4 |
| Obsevani / By radiotherapy | 750 | 61,0 | 814 | 66,8 | 726 | 67,8 | 791 | 70,6 | 757 | 70,2 | 3838 | 67,1 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

Thyroid *Thyroid Gland*

Table 5: Incidence of thyroid cancer by age, stage and treatment in 2018-2022, OI Ljubljana.Table 5: Incidence of thyroid cancer by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C73) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 176 | 100,0 | 188 | 100,0 | 172 | 100,0 | 196 | 100,0 | 225 | 100,0 | 957 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 3 | 1,7 | 6 | 3,2 | 5 | 2,9 | 2 | 1,0 | 6 | 2,7 | 22 | 2,3 |
| 20-49 | 86 | 48,9 | 76 | 40,4 | 64 | 37,2 | 77 | 39,3 | 74 | 32,9 | 377 | 39,4 |
| 50-74 | 66 | 37,5 | 88 | 46,8 | 81 | 47,1 | 96 | 49,0 | 118 | 52,4 | 449 | 46,9 |
| 75+ | 21 | 11,9 | 18 | 9,6 | 22 | 12,8 | 21 | 10,7 | 27 | 12,0 | 109 | 11,4 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 127 | 72,2 | 144 | 76,6 | 125 | 72,7 | 149 | 76,0 | 177 | 78,7 | 722 | 75,4 |
| Extended / Regional | 39 | 22,2 | 38 | 20,2 | 43 | 25,0 | 39 | 19,9 | 43 | 19,1 | 202 | 21,1 |
| Razsejan / Distant | 10 | 5,7 | 6 | 3,2 | 4 | 2,3 | 5 | 2,6 | 5 | 2,2 | 30 | 3,1 |
| Neznan / Unknown | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 3 | 1,5 | 0 | 0,0 | 3 | 0,3 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 160 | 90,9 | 174 | 92,6 | 160 | 93,0 | 185 | 94,4 | 210 | 93,3 | 889 | 92,9 |
| Operirani\*\* / By surgery\*\* | 143 | 81,3 | 148 | 78,7 | 125 | 72,7 | 169 | 86,2 | 186 | 82,7 | 771 | 80,6 |
| Treated with systemic therapy  By systemic therapy | 145 | 82,4 | 148 | 78,7 | 129 | 75,0 | 169 | 86,2 | 185 | 82,2 | 776 | 81,1 |
| Obsevani / By radiotherapy | 104 | 59,1 | 131 | 69,7 | 116 | 67,4 | 112 | 57,1 | 122 | 54,2 | 585 | 61,1 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

Cutaneous melanoma *Skin Melanoma*

Table 6: Incidence ofcutaneous melanoma by age, stage and treatment in 2018-2022, OI Ljubljana. Table 6: Incidence of skin melanoma by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C43) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 400 | 100,0 | 413 | 100,0 | 426 | 100,0 | 440 | 100,0 | 505 | 100,0 | 2184 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 1 | 0,3 | 2 | 0,5 | 3 | 0,7 | 4 | 0,9 | 3 | 0,6 | 13 | 0,6 |
| 20-49 | 87 | 21,8 | 80 | 19,4 | 77 | 18,1 | 80 | 18,2 | 108 | 21,4 | 432 | 19,8 |
| 50-74 | 190 | 47,5 | 228 | 55,2 | 223 | 52,3 | 233 | 53,0 | 252 | 49,9 | 1126 | 51,6 |
| 75+ | 122 | 30,5 | 103 | 24,9 | 123 | 28,9 | 123 | 28,0 | 142 | 28,1 | 613 | 28,1 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 239 | 59,8 | 256 | 62,0 | 278 | 65,3 | 267 | 60,7 | 343 | 67,9 | 1383 | 63,3 |
| Extended / Regional | 135 | 33,8 | 142 | 34,4 | 130 | 30,5 | 150 | 34,1 | 144 | 28,5 | 701 | 32,1 |
| Razsejan / Distant | 21 | 5,3 | 14 | 3,4 | 14 | 3,3 | 20 | 4,5 | 15 | 3,0 | 84 | 3,8 |
| Neznan / Unknown | 5 | 1,3 | 1 | 0,2 | 4 | 0,9 | 3 | 0,7 | 3 | 0,6 | 16 | 0,7 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 315 | 78,8 | 331 | 80,1 | 327 | 76,8 | 361 | 82,0 | 375 | 74,3 | 1709 | 78,3 |
| Operirani\*\* / By surgery\*\* | 297 | 74,3 | 321 | 77,7 | 314 | 73,7 | 347 | 78,9 | 359 | 71,1 | 1638 | 75,0 |
| Treated with systemic therapy  By systemic therapy | 36 | 9,0 | 61 | 14,8 | 46 | 10,8 | 81 | 18,4 | 54 | 10,7 | 278 | 12,7 |
| Obsevani / By radiotherapy | 37 | 9,3 | 41 | 9,9 | 38 | 8,9 | 34 | 7,7 | 24 | 4,8 | 174 | 8,0 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Gynaecological cancers / Gynaecological Cancers

250

200



150

Number / Number

100



50

0

2013 2014 2015 2016

2017

Year

2018

2019 2020 2021 2022

Cervix cervix (C53) Cervix uteri

Ovary (C56) Ovary

Corpus uteri (C54) Corpus uteri

Other (C51, C52, C55, C57, C58)

Other

Figure 9: Incidence of gynaecological cancers 2013-2022, OI Ljubljana.

Figure 9: Incidence of gynaecological cancers in the period 2013-2022, OI Ljubljana.

Table 7: Incidence ofgynaecological cancers by age, stage and treatment in 2018-2022, OI Ljubljana. Table 7: Incidence of gynaecological cancers by age, stage and treatment in the period 2018-2022,

OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C51-C58) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 435 | 100,0 | 458 | 100,0 | 419 | 100,0 | 472 | 100,0 | 437 | 100,0 | 2221 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 0 | 0,0 | 1 | 0,2 | 3 | 0,7 | 2 | 0,4 | 2 | 0,5 | 8 | 0,4 |
| 20-49 | 50 | 11,5 | 53 | 11,6 | 60 | 14,3 | 70 | 14,8 | 52 | 11,9 | 285 | 12,8 |
| 50-74 | 267 | 61,4 | 302 | 65,9 | 256 | 61,1 | 298 | 63,1 | 284 | 65,0 | 1407 | 63,3 |
| 75+ | 118 | 27,1 | 102 | 22,3 | 100 | 23,9 | 102 | 21,6 | 99 | 22,7 | 521 | 23,5 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 157 | 36,1 | 173 | 37,8 | 137 | 32,7 | 195 | 41,3 | 144 | 33,0 | 806 | 36,3 |
| Extended / Regional | 171 | 39,3 | 147 | 32,1 | 151 | 36,0 | 137 | 29,0 | 146 | 33,4 | 752 | 33,9 |
| Razsejan / Distant | 107 | 24,6 | 134 | 29,3 | 127 | 30,3 | 138 | 29,2 | 146 | 33,4 | 652 | 29,4 |
| Neznan / Unknown | 0 | 0,0 | 4 | 0,9 | 4 | 1,0 | 2 | 0,4 | 1 | 0,2 | 11 | 0,5 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 392 | 90,1 | 421 | 91,9 | 375 | 89,5 | 429 | 90,9 | 391 | 89,5 | 2008 | 90,4 |
| Operirani\*\* / By surgery\*\* | 114 | 26,2 | 142 | 31,0 | 123 | 29,4 | 146 | 30,9 | 128 | 29,3 | 653 | 29,4 |
| Treated with systemic therapy  By systemic therapy | 161 | 37,0 | 207 | 45,2 | 169 | 40,3 | 194 | 41,1 | 194 | 44,4 | 925 | 41,6 |
| Obsevani / By radiotherapy | 234 | 53,8 | 234 | 51,1 | 225 | 53,7 | 240 | 50,8 | 216 | 49,4 | 1149 | 51,7 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Urological Cancers / Urological Cancers

800

700

600

500

Number / Number

400

300

200

100

0

2013 2014 2015 2016

2017

Year

2018

2019 2020 2021 2022

Prostate (C61) Prostate

Modo (C62) Testis

Urinary bladder (C67) Bladder

Kidney (C64-C65) Kidney

Other (C60, C63, C66, C68)

Other

Figure 10: Incidence of urological cancers in the period 2013-2022, OI Ljubljana.

Figure 10: Incidence of urological cancers in the period 2013-2022, OI Ljubljana.

Table 8: Incidence of urological cancers by age, stage and treatment in 2018-2022, OI Ljubljana.Table 8: Incidence of urological cancers by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C60-C68) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 938 | 100,0 | 1067 | 100,0 | 885 | 100,0 | 993 | 100,0 | 1006 | 100,0 | 4889 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 6 | 0,6 | 6 | 0,6 | 5 | 0,6 | 6 | 0,6 | 1 | 0,1 | 24 | 0,5 |
| 20-49 | 89 | 9,5 | 126 | 11,8 | 107 | 12,1 | 131 | 13,2 | 121 | 12,0 | 574 | 11,7 |
| 50-74 | 568 | 60,6 | 616 | 57,7 | 483 | 54,6 | 542 | 54,6 | 576 | 57,3 | 2785 | 57,0 |
| 75+ | 275 | 29,3 | 319 | 29,9 | 290 | 32,8 | 314 | 31,6 | 308 | 30,6 | 1506 | 30,8 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 450 | 48,0 | 500 | 46,9 | 409 | 46,2 | 447 | 45,0 | 502 | 49,9 | 2308 | 47,2 |
| Extended / Regional | 334 | 35,6 | 375 | 35,1 | 296 | 33,4 | 357 | 36,0 | 320 | 31,8 | 1682 | 34,4 |
| Razsejan / Distant | 143 | 15,2 | 182 | 17,1 | 170 | 19,2 | 177 | 17,8 | 180 | 17,9 | 852 | 17,4 |
| Neznan / Unknown | 11 | 1,2 | 10 | 0,9 | 10 | 1,1 | 12 | 1,2 | 4 | 0,4 | 47 | 1,0 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 733 | 78,1 | 809 | 75,8 | 655 | 74,0 | 763 | 76,8 | 789 | 78,4 | 3749 | 76,7 |
| Operirani\*\* / By surgery\*\* | 7 | 0,7 | 9 | 0,8 | 19 | 2,1 | 14 | 1,4 | 9 | 0,9 | 58 | 1,2 |
| Treated with systemic therapy  By systemic therapy | 594 | 63,3 | 666 | 62,4 | 524 | 59,2 | 591 | 59,5 | 613 | 60,9 | 2988 | 61,1 |
| Obsevani / By radiotherapy | 505 | 53,8 | 495 | 46,4 | 373 | 42,1 | 473 | 47,6 | 499 | 49,6 | 2345 | 48,0 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Central Nervous System Tumours Central Nervous System Tumours

180

160



140

120

Number / Number

100

80

60

40

20

0



2013 2014 2015 2016

2017

Year

2018

2019 2020 2021 2022

Brain (C71) Brain

Other (C70, C72)

Other

Figure 11: Incidence ofcentral nervous system tumours 2013-2022, OI Ljubljana. Figure 11: Incidence of central nervous system tumours in the period 2013-2022, OI Ljubljana.

Table 9: Incidence ofcentral nervous system tumours by age, stage and treatment in 2018-2022, OI Ljubljana.

Table 9: Incidence of central nervous system tumours by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C70-C72) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 138 | 100,0 | 143 | 100,0 | 145 | 100,0 | 138 | 100,0 | 139 | 100,0 | 703 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 13 | 9,4 | 2 | 1,4 | 13 | 9,0 | 5 | 3,6 | 7 | 5,0 | 40 | 5,7 |
| 20-49 | 34 | 24,6 | 34 | 23,8 | 34 | 23,4 | 28 | 20,3 | 30 | 21,6 | 160 | 22,8 |
| 50-74 | 72 | 52,2 | 82 | 57,3 | 80 | 55,2 | 85 | 61,6 | 87 | 62,6 | 406 | 57,8 |
| 75+ | 19 | 13,8 | 25 | 17,5 | 18 | 12,4 | 20 | 14,5 | 15 | 10,8 | 97 | 13,8 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 138 | 100,0 | 142 | 99,3 | 145 | 100,0 | 137 | 99,3 | 138 | 99,3 | 700 | 99,6 |
| Extended / Regional | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 0,7 | 0 | 0,0 | 1 | 0,1 |
| Razsejan / Distant | 0 | 0,0 | 1 | 0,7 | 0 | 0,0 | 0 | 0,0 | 1 | 0,7 | 2 | 0,3 |
| Neznan / Unknown | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 108 | 78,3 | 123 | 86,0 | 119 | 82,1 | 113 | 81,9 | 119 | 85,6 | 582 | 82,8 |
| Operirani\*\* / By surgery\*\* | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
| Treated with systemic therapy  By systemic therapy | 73 | 52,9 | 91 | 63,6 | 69 | 47,6 | 88 | 63,8 | 77 | 55,4 | 398 | 56,6 |
| Obsevani / By radiotherapy | 104 | 75,4 | 119 | 83,2 | 113 | 77,9 | 106 | 76,8 | 105 | 75,5 | 547 | 77,8 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

# Soft Tissue and Bone Tumours Tumours

90



80

70

60

Number / Number

50

40

30

20



10



0

2013 2014 2015 2016

2017

Year

2018

2019 2020 2021 2022

Soft tissue (C47-C49) Soft tissue

Bone and articular cartilage (C40-C41) Bone and articular cartilage

Kaposi's sarcoma (C46) Kaposi's sarcoma

Figure 12: Incidence of soft tissue and bone tumours 2013-2022, OI Ljubljana.Figure 12: Incidence of soft tissue and bone tumours in the period 2013-2022, OI Ljubljana.

Table 10: Incidence of soft tissue and bone tumours by age, stage and treatment in 2018-2022, OI Ljubljana.

Table 10: Incidenceof soft tissue and bone tumours by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C40-C41, C46-C49) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 94 | 100,0 | 104 | 100,0 | 102 | 100,0 | 79 | 100,0 | 92 | 100,0 | 471 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 5 | 5,3 | 5 | 4,8 | 4 | 3,9 | 9 | 11,4 | 8 | 8,7 | 31 | 6,6 |
| 20-49 | 18 | 19,1 | 21 | 20,2 | 17 | 16,7 | 15 | 19,0 | 33 | 35,9 | 104 | 22,1 |
| 50-74 | 49 | 52,1 | 55 | 52,9 | 56 | 54,9 | 40 | 50,6 | 35 | 38,0 | 235 | 49,9 |
| 75+ | 22 | 23,4 | 23 | 22,1 | 25 | 24,5 | 15 | 19,0 | 16 | 17,4 | 101 | 21,4 |
| Stadij / Stage | | | | | | | | | | | | |
| Limited / Localised | 24 | 25,5 | 35 | 33,7 | 26 | 25,5 | 12 | 15,2 | 25 | 27,2 | 122 | 25,9 |
| Extended / Regional | 45 | 47,9 | 54 | 51,9 | 52 | 51,0 | 43 | 54,4 | 48 | 52,2 | 242 | 51,4 |
| Razsejan / Distant | 23 | 24,5 | 13 | 12,5 | 23 | 22,5 | 24 | 30,4 | 18 | 19,6 | 101 | 21,4 |
| Neznan / Unknown | 2 | 2,1 | 2 | 1,9 | 1 | 1,0 | 0 | 0,0 | 1 | 1,1 | 6 | 1,3 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 75 | 79,8 | 83 | 79,8 | 88 | 86,3 | 65 | 82,3 | 69 | 75,0 | 380 | 80,7 |
| Operirani\*\* / By surgery\*\* | 42 | 44,7 | 52 | 50,0 | 49 | 48,0 | 36 | 45,6 | 39 | 42,4 | 218 | 46,3 |
| Treated with systemic therapy  By systemic therapy | 28 | 29,8 | 21 | 20,2 | 21 | 20,6 | 26 | 32,9 | 14 | 15,2 | 110 | 23,4 |
| Obsevani / By radiotherapy | 51 | 54,3 | 56 | 53,8 | 50 | 49,0 | 36 | 45,6 | 40 | 43,5 | 233 | 49,5 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

Malignant neoplasms of lymphoid, haematopoietic and related tissue Malignant neoplasms of lymphoid, haematopoietic and related tissue

450

400



350

300

Number / Number

250

200

150

100



50

0

2013 2014 2015 2016

2017

Year

2018

2019 2020 2021 2022

Hodgkin's lymphoma (C81) Hodgkin's lymphoma

Non-Hodgkin's lymphomas (C82-C85) Non-Hodgkin's lymphoma

Plasmacytoma (C90) Multiple myeloma

Leukaemias (C91-C95) Leukaemias

MDS\* (C96) MDS

\*Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues. / \*Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.

Figure 13: Incidence of malignant neoplasms of lymphoid, haematopoietic and related tissues 2013-2022, OI Ljubljana.

Figure 13: Incidence of malignant neoplasms of lymphoid, haematopoietic and related tissue in the period 2013-2022, OI Ljubljana.

Table 11: Incidence of malignant neoplasms of lymphoid haematopoietic and related tissue by age, stage and treatment in 2018-2022, OI Ljubljana.

Table 11: Incidenceof malignant neoplasms of lymphoid, haematopoietic and related tissue by age, stage and treatment in the period 2018-2022, OI Ljubljana.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Number of new cases\* Number of new cases\* (C81-C85, C90-C96) | 2018 | | 2019 | | 2020 | | 2021 | | 2022 | | 2018-2022 | |
| No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % | No. / No. | % |
| 528 | 100,0 | 545 | 100,0 | 540 | 100,0 | 577 | 100,0 | 554 | 100,0 | 2744 | 100,0 |
| Age / Age | | | | | | | | | | | | |
| 0-19 | 23 | 4,4 | 15 | 2,8 | 18 | 3,3 | 26 | 4,5 | 19 | 3,4 | 101 | 3,7 |
| 20-49 | 92 | 17,4 | 82 | 15,0 | 95 | 17,6 | 95 | 16,5 | 84 | 15,2 | 448 | 16,3 |
| 50-74 | 293 | 55,5 | 309 | 56,7 | 280 | 51,9 | 319 | 55,3 | 315 | 56,9 | 1516 | 55,2 |
| 75+ | 120 | 22,7 | 139 | 25,5 | 147 | 27,2 | 137 | 23,7 | 136 | 24,5 | 679 | 24,7 |
| Stage (C81-C85) | | | | | | | | | | | | |
| No. of new cases\* (C81-C85) | 432 | 100,0 | 454 | 100,0 | 430 | 100,0 | 468 | 100,0 | 456 | 100,0 | 2240 | 100,0 |
| I | 80 | 18,5 | 97 | 21,4 | 83 | 19,3 | 92 | 19,7 | 102 | 22,4 | 454 | 20,3 |
| II | 61 | 14,1 | 79 | 17,4 | 65 | 15,1 | 73 | 15,6 | 67 | 14,7 | 345 | 15,4 |
| III+IV | 266 | 61,6 | 272 | 59,9 | 274 | 63,7 | 294 | 62,8 | 280 | 61,4 | 1386 | 61,9 |
| Neznan / Unknown | 25 | 5,8 | 6 | 1,3 | 8 | 1,9 | 9 | 1,9 | 7 | 1,5 | 55 | 2,5 |
| Treatment / Treatment | | | | | | | | | | | | |
| However treated All treated | 381 | 72,2 | 383 | 70,3 | 382 | 70,7 | 413 | 71,6 | 384 | 69,3 | 1943 | 70,8 |
| Operirani\*\* / By surgery\*\* | 11 | 2,1 | 14 | 2,6 | 13 | 2,4 | 13 | 2,3 | 7 | 1,3 | 58 | 2,1 |
| Treated with systemic therapy  By systemic therapy | 292 | 55,3 | 301 | 55,2 | 301 | 55,7 | 308 | 53,4 | 296 | 53,4 | 1498 | 54,6 |
| Obsevani / By radiotherapy | 196 | 37,1 | 186 | 34,1 | 163 | 30,2 | 199 | 34,5 | 167 | 30,1 | 911 | 33,2 |

\*Patients admitted for the first time in the year shown. / Patients first admitted to OI Ljubljana in a shown year.

\*\*Curative and palliative surgery. / Curative and palliative surgery.

Distribution of cancers by sex and age

*Cancer by Sex and Age*

Brain and central nervous system Brain and central nervous system

2,8 %

1,4 %

Women Men

2,6%

8,9 %

Females Males

n = 3293 n = 3366

1,8 %

4,9%

10,7%

14,3 %

0,2 %

32,5 %

10,7 %

17,5

1,9 %

4,8 %

13,3 %

23,3%

12,6 %

16,4 %

8,5 %

8,1 %

1,4 %

1,3 %

0

5

10

15

20

25

30

35

40 %

%

C70-C72

Head and neck

C00-C14, C30-C32, C69

Thyroid gland / Thyroid gland

C73

Thoracic organs / Thoracic organs

C33-C34, C37-C39, C45

Breastfeeding / Breast

C50

Digestive organs / Digestive organs

C15-C26

Urinary tract / Urinary tract

C64-C68

Sexual organs / Genital organs

males C60-C63, females C51-C58

Bone, soft tissue, skin

C40-C44, C46-C49

Lymphoid, haematopoietic and related tissue Lymphoid, haematopoietic and related tissue

C81-C96

Other / Other

C74-C80


Figure 14: Percentagedistribution of all cancers by sex and site, OI Ljubljana 2022 Figure 14: Percentage distribution of all cancers by sex and site, OI Ljubljana 2022.

50



55,1 %

45,3 %



85+ 0-34

5,9 % 3,7 %

35-49

years / yrs

11,2 %

Total / All (M+W / M+F)

65-84

50,2 %

28,9 % 50–64

40



30

20

10

Women / Females

3,7 %

14,1 %

30,0 %

27,9 %

7,0 %

Men / Males

3,7 % 8,5 %

0

4,8 %

0-34 35-49 50-64 65-84 85+ years

Figure 15: Percentage of all cancers by age group and sex, OI Ljubljana 2022.Figure 15: Percentage of all cancers by age group and sex, OI Ljubljana 2022.

Incidence

*Incidence*

Table 12: Cancer incidenceby site, sex and age, OI Ljubljana 2022.Table 12: incidence by site, sex and age, OI Ljubljana 2022.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MKB code | Primary location | Gender | All ages | Age / Age | | | | | | | | | | | | | | | | | |
| ICD code | Primary site | Sex | All ages | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ |
| C00-C96 | All sites All sites | M+F | 6659 | 11 | 6 | 13 | 26 | 37 | 65 | 88 | 156 | 246 | 347 | 467 | 655 | 806 | 1029 | 1028 | 729 | 557 | 393 |
| M Ž | 3366  3293 | 7  4 | 3  3 | 5  8 | 10  16 | 22  15 | 35  30 | 43  45 | 61  95 | 89  157 | 136  211 | 196  271 | 322  333 | 421  385 | 576  453 | 591  437 | 411  318 | 275  282 | 163  230 |
| C00 | Lip | M | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| Lip | Ž | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 3 |
| C01 | Language base | M | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 4 | 2 | 4 | 0 | 0 | 0 |
| Base of tongue | Ž | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| C02 | Language, other parts  Tongue, other & unspecified parts | M Ž | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 6 | 7 | 2 | 0 | 1 | 0 |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 |
| C03 | Dlesen | M | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Gum | Ž | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 |
| C04 | Mouth base | M | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 7 | 6 | 2 | 0 | 0 | 0 |
| Floor of mouth | Ž | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 0 |
| C05 | Or | M | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 3 | 0 | 0 |
| Palate | Ž | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 1 |
| C06 | Mouth, other parts | M | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 4 | 2 | 0 | 1 | 0 |
| Mouth, other & unspecified parts | Ž | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
| C07 | Parotid gland | M | 8 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 1 | 1 |
| Parotid gland | Ž | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 0 | 0 |
| C08 | Other and unspecified major salivary glands  Other & unspecified major salivary glands | M  Ž | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C09 | Tonzila | M | 51 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 5 | 6 | 7 | 6 | 7 | 7 | 6 | 1 | 2 |
| Tonsil | Ž | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 5 | 3 | 0 | 0 | 2 | 0 |
| C10 | Orofarinx | M | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 5 | 5 | 4 | 6 | 0 | 0 | 0 |
| Oropharynx | Ž | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 0 |
| C11 | Nazopharinx | M | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 4 | 1 | 0 | 0 | 0 |
| Nasopharynx | Ž | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| C12 | Pyriform sinus | M | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 4 | 6 | 3 | 0 | 1 | 1 | 0 |
| Pyriform sinus | Ž | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| C13 | Hypofarinx | M | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 3 | 3 | 1 | 0 |
| Hypopharynx | Ž | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
|  | Other and ill-defined sites on the lip, oral cavity and pharynx  Other and ill-defined sites in the lip, oral cavity  and pharynx | M  Ž | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C14 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C15 | Firewall | M | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 6 | 5 | 5 | 7 | 6 | 4 | 1 | 0 |
| Oesophagus | Ž | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 3 | 2 | 2 | 0 | 0 |
| C16 | Stomach | M | 86 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 3 | 8 | 11 | 16 | 18 | 13 | 7 | 5 | 0 |
| Stomach | Ž | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 3 | 6 | 5 | 10 | 3 | 4 | 1 |
| C17 | Small intestine | M | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 3 | 0 | 2 | 3 | 0 | 0 |
| Small intestine | Ž | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 2 | 1 | 1 | 0 |
| C18 | Large intestine | M | 133 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 3 | 2 | 19 | 13 | 9 | 21 | 15 | 19 | 14 | 12 | 3 |
| Colon | Ž | 115 | 0 | 1 | 1 | 1 | 0 | 3 | 0 | 4 | 7 | 8 | 6 | 8 | 14 | 13 | 20 | 8 | 17 | 4 |
| C19 | The rectosigmoid union | M | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 5 | 2 | 1 | 2 | 1 | 3 | 0 |
| Rectosigmoid junction | Ž | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 1 | 1 | 2 | 2 | 0 |
| C20 | Rektum | M | 154 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 6 | 15 | 25 | 23 | 27 | 15 | 16 | 15 | 5 |
| Rectum | Ž | 68 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 | 9 | 7 | 8 | 8 | 10 | 5 | 8 | 7 |
| C21 | Anus and anal canal | M | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Anus and anal canal | Ž | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 1 | 2 | 3 | 1 | 1 | 2 | 0 |
| C22 | Liver and intrahepatic ducts | M | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 6 | 15 | 4 | 2 | 0 |
| Liver and intrahepatic bile ducts | Ž | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 3 | 1 | 2 | 8 | 0 | 0 | 0 |
| C23 | Gallbladder | M | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Gallbladder | Ž | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 1 |

Continued ->

Table 12: Continued.

Table 12: Continued.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MKB code | Primary location | Gender | All ages | Age / Age | | | | | | | | | | | | | | | | | |
| ICD code | Primary site | Sex | All ages | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ |
| C24 | Other and unspecified parts of the biliary tract  Billiary tract, other and unspecified parts | M  Ž | 20  13 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 2  0 | 4  0 | 3  1 | 5  2 | 3  3 | 2  5 | 0  2 | 1  0 |
| C25 | Pancreas Pancreas | M Ž | 85  47 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 1  0 | 3  0 | 3  2 | 6  3 | 8  7 | 11  6 | 22  7 | 16  15 | 9  4 | 4  3 | 1  0 |
| C26 | Other and ill-defined sites in digestive organs Other and ill-defined  digestive organs | M  Ž | 1  2 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  1 | 0  0 | 0  0 | 0  0 |
| C30 | Nasal cavity and middle ear Nasal cavity and middle ear | M Ž | 12  7 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  1 | 0  0 | 0  0 | 4  1 | 1  0 | 3  0 | 1  2 | 0  2 | 1  1 | 1  0 |
| C31 | Paranasal sinuses Accessory sinuses | M Ž | 4  5 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 1  0 | 1  2 | 1  0 | 0  1 | 1  1 |
| C32 | Larynx throat | M Ž | 65  10 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 2  1 | 7  1 | 13  1 | 9  0 | 15  3 | 7  2 | 7  1 | 3  0 | 1  1 |
| C33 | Sapnik Trachea | M Ž | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C34 | Trachea and lung Bronchus and lung | M Ž | 462  337 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 1  3 | 8  3 | 21  9 | 42  43 | 69  52 | 112  87 | 99  56 | 59  43 | 33  34 | 17  7 |
| C37 | Timus Thymus | M Ž | 2  4 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  0 | 0  0 | 0  1 | 0  1 | 1  1 | 0  0 | 0  0 |
| C38 | Heart, mediastinum, pleura Heart, mediastinum, pleura | M Ž | 1  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C39 | Other and ill-defined sites in respiratory and thoracic organs Other and ill-defined sites in  the respiratory system and  intrathoracic organs | M  Ž | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C40 | Bones, articular cartilage of limbs  Bone and articular cartilage of limbs | M Ž | 5  3 | 0  0 | 0  0 | 0  1 | 1  0 | 2  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  0 | 0  0 |
| C41 | Bone, articular cartilage, elsewhere  Bone and articular cartilage of other and unspecified parts | M  Ž | 8  7 | 0  0 | 0  0 | 0  1 | 1  0 | 0  0 | 0  0 | 1  0 | 1  0 | 0  1 | 0  0 | 2  1 | 0  0 | 0  0 | 1  1 | 1  1 | 1  1 | 0  0 | 0  1 |
| C43 | Malignant melanoma of the skin Malignant melanoma of the skin | M Ž | 278  227 | 0  0 | 0  0 | 0  0 | 1  2 | 1  2 | 2  3 | 3  1 | 6  16 | 18  16 | 18  22 | 23  15 | 23  14 | 31  20 | 41  23 | 30  32 | 39  17 | 20  18 | 22  26 |
| C44 | Other malignant neoplasms of the skin Skin, excl. melanoma | M Ž | 215  156 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 2  0 | 1  0 | 2  3 | 1  4 | 1  4 | 6  3 | 15  2 | 12  12 | 28  9 | 31  12 | 24  16 | 37  34 | 54  57 |
| C45 | Mesothelioma Mesothelioma | M Ž | 17  9 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  0 | 0  1 | 0  0 | 0  2 | 0  0 | 4  2 | 2  1 | 6  0 | 4  1 | 0  0 | 0  1 |
| C46 | Kaposi's sarcoma Kaposi's sarcoma | M Ž | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C47 | Peripheral nerves and autonomic nervous system  Peripheral nerves and  autonomic nervous system | M Ž | 1  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 |
| C48 | Peritoneum and retroperitoneum  Retroperitoneum and peritoneum | M Ž | 11  5 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 1  1 | 1  0 | 0  0 | 0  1 | 1  1 | 2  2 | 0  0 | 3  0 | 1  0 | 0  0 |
| C49 | Other connective and soft tissue Other connective and soft tissue | M Ž | 34  16 | 0  1 | 0  0 | 1  0 | 1  0 | 0  1 | 1  0 | 0  2 | 3  1 | 3  1 | 6  3 | 2  1 | 2  0 | 1  2 | 4  0 | 4  3 | 1  0 | 2  0 | 3  1 |
| C50 | Breastfeeding Breast | M Ž | 8  1071 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  4 | 0  17 | 0  41 | 0  81 | 0  106 | 1  120 | 1  120 | 1  124 | 1  136 | 2  94 | 0  90 | 2  76 | 0  61 |
| C51 | Female external genitalia Vulva | M Ž | - 34 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 1 | - 2 | - 1 | - 2 | - 2 | - 2 | - 6 | - 4 | - 6 | - 8 |
| C52 | Vagina Scissors | M Ž | - 6 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 1 | - 0 | - 0 | - 0 | - 0 | - 1 | - 0 | - 3 | - 0 | - 0 | - 1 |
| C53 | Cervix cervix uteri | M Ž | - 60 | - 0 | - 0 | - 0 | - 0 | - 0 | - 2 | - 2 | - 4 | - 3 | - 6 | - 7 | - 4 | - 9 | - 3 | - 11 | - 2 | - 4 | - 3 |
| C54 | Corpus uteri | M Ž | - 190 | - 0 | - 0 | - 0 | - 0 | - 1 | - 0 | - 1 | - 1 | - 5 | - 3 | - 23 | - 31 | - 16 | - 29 | - 34 | - 19 | - 17 | - 10 |
| C55 | Uterus, unspecified Uterus, unspecified | M Ž | - 4 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 1 | - 0 | - 1 | - 2 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 |
| C56 | Ovary Ovary | M Ž | - 105 | - 0 | - 0 | - 0 | - 2 | - 0 | - 1 | - 0 | - 3 | - 4 | - 6 | - 12 | - 8 | - 16 | - 19 | - 15 | - 11 | - 5 | - 3 |

Continued ->

Table 12: Continued.

Table 12: Continued.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MKB code | Primary location | Gender | All ages | Age / Age | | | | | | | | | | | | | | | | | |
| ICD code | Primary site | Sex | All ages | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ |
| C57 | Other and unspecified female genital organs  Other and unspecified parts of female genital organs | M  Ž | -  38 | -  0 | -  0 | -  0 | -  0 | -  0 | -  0 | -  0 | -  1 | -  2 | -  2 | -  2 | -  6 | -  8 | -  7 | -  4 | -  3 | -  3 | -  0 |
| C58 | Placenta bed | M Ž | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 | - 0 |
| C60 | Penis Penis | M Ž | 4 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 1 - | 1 - | 1 - | 0 - | 0 - | 0 - | 1 - |
| C61 | Prostate Prostate | M Ž | 647 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 0 - | 3 - | 9 - | 32 - | 70 - | 115 - | 181 - | 141 - | 72 - | 24 - |
| C62 | Modo Testis | M Ž | 130 - | 0 - | 0 - | 0 - | 0 - | 11 - | 16 - | 25 - | 21 - | 21 - | 17 - | 8 - | 6 - | 2 - | 1 - | 1 - | 0 - | 1 - | 0 - |
| C63 | Other and unspecified male genital organs  Other and unspecified male genital organs | M  Ž | 2  - | 0  - | 0  - | 0  - | 0  - | 0  - | 0  - | 0  - | 1  - | 0  - | 0  - | 0  - | 1  - | 0  - | 0  - | 0  - | 0  - | 0  - | 0  - |
| C64 | Kidney, excl. renal pelvis Kidney, excl. renal pelvis | M Ž | 70  23 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 1  0 | 3  1 | 0  0 | 2  1 | 12  4 | 13  4 | 15  1 | 15  1 | 6  5 | 1  3 | 1  2 |
| C65 | Renal bladder Renal pelvis | M Ž | 7  4 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 2  0 | 1  1 | 3  2 | 1  0 | 0  0 | 0  1 | 0  0 |
| C66 | Ureter ureter | M Ž | 3  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 1  0 | 1  0 | 0  0 | 0  0 | 0  1 |
| C67 | Bladder Bladder | M Ž | 79  33 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 5  1 | 14  4 | 12  4 | 14  8 | 11  8 | 14  6 | 8  2 |
| C68 | Other and unspecified urinary organs  Other and unspecified urinary organs | M  Ž | 2  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 2  0 | 0  0 | 0  0 | 0  0 |
| C69 | Eye and adnexa Eye and adnexa | M Ž | 3  2 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  0 | 0  0 | 1  0 | 1  0 | 0  1 | 0  0 | 0  0 |
| C70 | Meninge Meninges | M Ž | 1  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 |
| C71 | Brain Brain | M Ž | 91  42 | 3  0 | 0  1 | 1  1 | 0  1 | 1  0 | 2  0 | 3  4 | 3  1 | 5  3 | 7  0 | 10  2 | 11  6 | 11  6 | 11  8 | 14  4 | 4  5 | 4  0 | 1  0 |
| C72 | Spinal cord, cerebral nerves and other parts of the CNS  Spinal cord, cranial nerves and other parts of CNS | M  Ž | 1  3 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 1  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 |
| C73 | Thyroid Thyroid gland | M Ž | 62  163 | 0  0 | 0  0 | 2  2 | 0  2 | 0  6 | 2  9 | 2  7 | 6  11 | 6  4 | 4  17 | 9  13 | 8  21 | 7  14 | 6  15 | 7  18 | 1  13 | 2  5 | 0  6 |
| C74 | Adrenal gland Adrenal gland | M Ž | 2  4 | 1  2 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 1  0 | 0  0 | 0  0 | 0  0 |
| C75 | Other endocrine glands and related structures  Other endocrine glands and related structures | M  Ž | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C76 | Other and poorly defined sites  Other and ill-defined sites | M Ž | 1  4 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 1  1 | 0  0 | 0  0 |
| C77 | Metastasis and unspecified malignant neoplasm of lymph nodes Metastasis and unspecified malignant neoplasm of lymph  nodes | M  Ž | 19  12 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  1 | 1  1 | 1  1 | 2  0 | 3  3 | 1  0 | 5  0 | 1  1 | 1  1 | 0  1 | 3  3 |
| C78 | Respiratory and gastrointestinal metastases  Metastases of respiratory and digestive organs | M Ž | 3  3 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  1 | 2  1 | 0  0 | 0  1 | 0  0 | 0  0 |
| C79 | Metastases of other sites Metastases of other sites | M Ž | 2  5 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  2 | 0  1 | 0  0 | 0  0 | 0  2 | 1  0 |
| C80 | Malignant neoplasm without defined site Malignant neoplasm without  specification of site | M  Ž | 20  13 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 2  0 | 0  1 | 3  3 | 0  2 | 7  2 | 3  0 | 3  1 | 2  1 | 0  2 |
| C81 | Hodgkin's lymphoma Hodgkin's lymphoma | M Ž | 28  29 | 0  0 | 0  0 | 0  0 | 3  2 | 2  0 | 2  6 | 2  5 | 1  2 | 2  3 | 3  4 | 2  2 | 3  1 | 1  1 | 2  2 | 2  0 | 0  1 | 3  0 | 0  0 |
| C82 | Follicular non-Hodgkin's lymphoma Follicular non-Hodgkin's lymphoma  lymphoma | M Ž | 55  68 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 2  0 | 2  2 | 4  6 | 4  9 | 4  4 | 6  11 | 11  11 | 7  16 | 9  6 | 3  1 | 3  1 |

Continued ->

Table 12: Continued.

Table 12: Continued.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MKB code | Primary location | Gender | All ages | Age / Age | | | | | | | | | | | | | | | | | |
| ICD code | Primary site | Sex | All ages | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ |
| C83 | Diffuse non-Hodgkin lymphoma  Ditfuse non-Hodgkin's lymphoma | M Ž | 125  113 | 1  0 | 0  1 | 0  0 | 0  0 | 0  1 | 2  0 | 2  0 | 1  1 | 1  2 | 3  7 | 9  7 | 14  6 | 21  14 | 18  17 | 21  15 | 10  16 | 16  14 | 6  12 |
| C84 | T-cell lymphomas and cutaneous T-cell lymphoma  Peripheral and cutaneous T-cell lymphomas | M  Ž | 18  16 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  1 | 0  0 | 0  1 | 0  0 | 0  0 | 2  1 | 3  0 | 1  1 | 3  2 | 3  6 | 1  1 | 3  2 | 1  1 |
| C85 | Other and unspecified types of non-Hodgkin's lymphoma Other and unspecified types of  non-Hodgkin's lymphoma | M  Ž | 0  4 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  1 | 0  0 | 0  0 | 0  0 | 0  1 | 0  1 | 0  0 |
| C88 | Malignant immunoproliferative diseases  Malignant immunoproliferative diseases | M  Ž | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C90 | Diffuse plasmacytoma and malignant neoplasms of the plasmacytes  Multiple myeloma and malignant plasma cell neoplasms | M  Ž | 24  13 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 4  0 | 3  0 | 3  3 | 4  2 | 2  4 | 4  2 | 3  2 | 0  0 |
| C91.0 | Lymphoblastic leukaemia Lymphoblastic leukaemia, acute | M Ž | 8  6 | 0  1 | 2  0 | 0  1 | 0  4 | 3  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 1  0 | 0  0 | 0  0 | 0  0 |
| C91.1- C91.9 | Lymphoid leukaemia, other Lymphoid leukaemia, other | M Ž | 22  10 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 2  0 | 0  0 | 0  1 | 3  0 | 2  2 | 5  1 | 3  2 | 5  3 | 1  0 | 0  1 |
| C92 | Myeloid leukaemia Myeloid leukaemia | M Ž | 2  5 | 0  0 | 0  0 | 0  0 | 0  2 | 0  2 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 |
| C93 | Monocytic leukaemia Monocytic leukaemia | M Ž | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C94 | Other defined leukaemias  Other leukaemias of specified cells | M  Ž | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 |
| C95 | Leukaemia with an undefined cell type  Leukaemia, unspecified cell type | M Ž | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| C96 | Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue  tissues | M  Ž | 5  2 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 1  0 | 0  0 | 1  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  1 | 0  0 |

Not included above:

Not included above:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MKB code | Primary location | Gender | All ages | Age / Age | | | | | | | | | | | | | | | | | |
| ICD code | Primary site | Sex | All ages | 0- | 5- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45- | 50- | 55- | 60- | 65- | 70- | 75- | 80- | 85+ |
| D03 | Melanoma, in situ Melanoma, in situ | M Ž | 18  23 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  2 | 0  4 | 1  5 | 1  2 | 7  5 | 1  0 | 1  2 | 2  1 | 1  1 | 2  0 | 1  1 |
| D05 | Breast, in situ Breast, in situ | M Ž | 2  124 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  2 | 0  6 | 0  8 | 0  33 | 0  27 | 0  23 | 0  20 | 0  1 | 2  2 | 0  2 | 0  0 |
| D06 | Cervix uteri, in situ (CIN III) Cervix uteri, in situ | M Ž | - 11 | - 0 | - 0 | - 0 | - 0 | - 0 | - 2 | - 1 | - 3 | - 2 | - 1 | - 0 | - 0 | - 0 | - 1 | - 0 | - 1 | - 0 | - 0 |
| D09.0 | Bladder, in situ Bladder, in situ | M Ž | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| D32.0, D42.0 | Meningeal neoplasms, benign neoplasms and neoplasms of uncertain character  Benign neoplasm and neoplasm of uncertain behaviour of meninges | M  Ž | 12  18 | 0  0 | 0  0 | 0  0 | 0  0 | 1  0 | 0  0 | 0  0 | 1  0 | 0  1 | 0  2 | 2  3 | 0  4 | 3  1 | 4  3 | 1  2 | 0  2 | 0  0 | 0  0 |
| D33.0- D33.2 | Brain, benign neoplasm Benign neoplasm of brain | M Ž | 3  1 | 1  0 | 2  0 | 0  0 | 0  0 | 0  1 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |
| D39.1 | Ovary, neoplasm of uncertain character Ovary, neoplasm of  uncertain behaviour | M  Ž | -  13 | -  0 | -  0 | -  0 | -  1 | -  0 | -  0 | -  0 | -  1 | -  1 | -  2 | -  2 | -  1 | -  2 | -  1 | -  2 | -  0 | -  0 | -  0 |
| D43.0- D43.2 | Brain, unspecified  Central nervous system (CNS), uncertain or unknown | M Ž | 6  2 | 1  0 | 1  0 | 1  1 | 1  1 | 1  0 | 1  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 | 0  0 |

Table 13: Incidence ofmicroscopically (histologically and cytologically) confirmed cancer cases by morphological type, OI Ljubljana 2022.

Table 13: Incidenceof microscopically (histologically and cytologically) confirmed cancer cases by morphological type, OI Ljubljana 2022.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Histological type Histologic type | Total All sites | Primary site (ICD code) Primary site (ICD code) | | | | | | | | | | | | | | | | | | |
| C00-C80 | C00 | C01 | C02 | C03 | C04 | C05 | C06 | C07 | C08 | C09 | C10 | C11 | C12 | C13 | C14 | C15 | C16 | C17 | C18 |
| All types | 6005 | 13 | 21 | 24 | 8 | 29 | 15 | 13 | 13 | 1 | 66 | 29 | 10 | 22 | 14 | 0 | 49 | 126 | 23 | 246 |
| Small cell carcinoma / Small cell carcinoma | 117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Non-small cell carcinoma Non-small cell carcinoma | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Squamous cell carcinoma Squamous cell carcinoma | 866 | 12 | 21 | 24 | 8 | 28 | 13 | 13 | 0 | 0 | 66 | 29 | 10 | 22 | 14 | 0 | 37 | 1 | 0 | 0 |
| Basal cell carcinoma / Basal cell carcinoma | 191 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Transitional cell carcinoma Transitional cell carcinoma | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adenocarcinoma / Adenocarcinoma | 3546 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 107 | 11 | 245 |
| Other specified carcinomas Other specified carcinomas | 90 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Carcinoma, unspecified | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Malignant thymoma / Malignant thymoma | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant paraganglioma/pheochromocytoma Malignant paraganglioma/pheochromocytoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant melanoma / Malignant melanoma | 524 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrosarcoma / Fibrosarcoma | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrohistiocytic sarcoma / Fibrohistiocytic sarcoma | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liposarcoma / Liposarcoma | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leiomyosarcoma / Leiomyosarcoma | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Rhabdomyosarcoma / Rhabdomyosarcoma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synovial sarcoma / Synovial sarcoma | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Angiosarcoma / Angiosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kaposi sarcoma / Kaposi sarcoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Osteosarcoma / Osteosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chondrosarcoma / Chondrosarcoma | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ewing sarcoma/PNET / Ewing sarcoma/PNET | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified sarcomas Other specified sarcomas | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sarkom, neopredeljen / Sarcoma, unspecified | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Complex mixed and stromal malignant tumours Malignant complex mixed and stromal tumours | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 11 | 0 |
| Fibroepithelial malignant tumours Malignant fibroepithelial tumours | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant mesothelioma Malignant mesothelioma | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gonadal stromal tumours Malignant gonadal stromal tumours | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dysgerminoma and seminoma Dysgerminoma and seminoma | 86 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other malignant germ cell tumours Other malignant germ cell tumours | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant trophoblastic tumours Malignant trophoblastic tumours | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gliomas / Malignant gliomas | 134 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant neuroepithelial tumours Malignant neuroepithelial tumours | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant meningioma Malignant meningioma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant nerve sheath tumours Malignant nerve sheath tumours | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified malignant tumours Other specified malignant tumours | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant tumour, unspecified Malignant tumour, unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Continued ->

Table 13: Continued.

Table 13: Continued.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Histological type Histologic type | Total All sites | Primary site (ICD code) Primary site (ICD code) | | | | | | | | | | | | | | | | | | |
| C00-C80 | C19 | C20 | C21 | C22 | C23 | C24 | C25 | C26 | C30 | C31 | C32 | C33 | C34 | C37 | C38 | C39 | C40 | C41 | C43 |
| All types | 6005 | 29 | 222 | 19 | 39 | 6 | 31 | 114 | 3 | 19 | 8 | 75 | 1 | 762 | 6 | 1 | 0 | 8 | 15 | 505 |
| Small cell sarcoma / Small cell carcinoma | 117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-small cell carcinoma Non-small cell carcinoma | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 0 | 0 | 0 | 0 | 0 | 0 |
| Squamous cell carcinoma Squamous cell carcinoma | 866 | 0 | 2 | 15 | 0 | 0 | 0 | 1 | 0 | 10 | 3 | 72 | 1 | 189 | 1 | 0 | 0 | 0 | 0 | 0 |
| Basal cell carcinoma / Basal cell carcinoma | 191 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Transitional cell carcinoma Transitional cell carcinoma | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adenocarcinoma / Adenocarcinoma | 3546 | 29 | 219 | 1 | 37 | 6 | 30 | 105 | 2 | 5 | 4 | 1 | 0 | 388 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified carcinomas Other specified carcinomas | 90 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 33 | 0 | 0 | 0 | 0 | 0 | 0 |
| Carcinoma, unspecified | 43 | 0 | 1 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant thymoma / Malignant thymoma | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Malignant paraganglioma/pheochromocytoma Malignant paraganglioma/pheochromocytoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant melanoma / Malignant melanoma | 524 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 505 |
| Fibrosarcoma / Fibrosarcoma | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrohistiocytic sarcoma / Fibrohistiocytic sarcoma | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liposarcoma / Liposarcoma | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leiomyosarcoma / Leiomyosarcoma | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Rhabdomyosarcoma / Rhabdomyosarcoma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synovial sarcoma / Synovial sarcoma | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Angiosarcoma / Angiosarcoma | 6 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kaposi sarcoma / Kaposi sarcoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Osteosarcoma / Osteosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 |
| Chondrosarcoma / Chondrosarcoma | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 0 |
| Ewing sarcoma/PNET / Ewing sarcoma/PNET | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Other specified sarcomas Other specified sarcomas | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sarkom, neopredeljen / Sarcoma, unspecified | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Complex mixed and stromal malignant tumours Malignant complex mixed and stromal tumours | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibroepithelial malignant tumours Malignant fibroepithelial tumours | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant mesothelioma Malignant mesothelioma | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gonadal stromal tumours Malignant gonadal stromal tumours | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dysgerminoma and seminoma Dysgerminoma and seminoma | 86 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other malignant germ cell tumours Other malignant germ cell tumours | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Malignant trophoblastic tumours Malignant trophoblastic tumours | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gliomas / Malignant gliomas | 134 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant neuroepithelial tumours Malignant neuroepithelial tumours | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant meningioma Malignant meningioma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant nerve sheath tumours Malignant nerve sheath tumours | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified malignant tumours Other specified malignant tumours | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 |
| Malignant tumour, unspecified Malignant tumour, unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Continued ->

Table 13: Continued.

Table 13: Continued.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Histological type Histologic type | Total All sites | Primary site (ICD code) Primary site (ICD code) | | | | | | | | | | | | | | | | | |
| C00-C80 | C44 | C45 | C46 | C47 | C48 | C49 | C50 | C51 | C52 | C53 | C54 | C55 | C56 | C57 | C58 | C60 | C61 | C62 |
| All types | 6005 | 370 | 26 | 1 | 2 | 15 | 50 | 1077 | 34 | 6 | 60 | 190 | 4 | 104 | 38 | 0 | 4 | 644 | 130 |
| Small cell sarcoma / Small cell carcinoma | 117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Non-small cell carcinoma Non-small cell carcinoma | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Squamous cell carcinoma Squamous cell carcinoma | 866 | 153 | 0 | 0 | 0 | 0 | 0 | 0 | 28 | 5 | 52 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
| Basal cell carcinoma / Basal cell carcinoma | 191 | 190 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Transitional cell carcinoma Transitional cell carcinoma | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adenocarcinoma / Adenocarcinoma | 3546 | 17 | 0 | 0 | 0 | 1 | 0 | 1054 | 4 | 0 | 6 | 151 | 0 | 90 | 35 | 0 | 0 | 643 | 0 |
| Other specified carcinomas Other specified carcinomas | 90 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 1 | 26 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Carcinoma, unspecified | 43 | 1 | 0 | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Malignant thymoma / Malignant thymoma | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant paraganglioma/pheochromocytoma Malignant paraganglioma/pheochromocytoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant melanoma / Malignant melanoma | 524 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrosarcoma / Fibrosarcoma | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrohistiocytic sarcoma / Fibrohistiocytic sarcoma | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liposarcoma / Liposarcoma | 22 | 0 | 0 | 0 | 0 | 8 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leiomyosarcoma / Leiomyosarcoma | 12 | 3 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rhabdomyosarcoma / Rhabdomyosarcoma | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Synovial sarcoma / Synovial sarcoma | 4 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Angiosarcoma / Angiosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kaposi sarcoma / Kaposi sarcoma | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Osteosarcoma / Osteosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chondrosarcoma / Chondrosarcoma | 7 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ewing sarcoma/PNET / Ewing sarcoma/PNET | 4 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified sarcomas Other specified sarcomas | 7 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Sarkom, neopredeljen / Sarcoma, unspecified | 19 | 4 | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Complex mixed and stromal malignant tumours Malignant complex mixed and stromal tumours | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Fibroepithelial malignant tumours Malignant fibroepithelial tumours | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant mesothelioma Malignant mesothelioma | 26 | 0 | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gonadal stromal tumours Malignant gonadal stromal tumours | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Dysgerminoma and seminoma Dysgerminoma and seminoma | 86 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 83 |
| Other malignant germ cell tumours Other malignant germ cell tumours | 40 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 35 |
| Malignant trophoblastic tumours Malignant trophoblastic tumours | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 12 |
| Malignant gliomas / Malignant gliomas | 134 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant neuroepithelial tumours Malignant neuroepithelial tumours | 6 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant meningioma Malignant meningioma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant nerve sheath tumours Malignant nerve sheath tumours | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified malignant tumours Other specified malignant tumours | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant tumour, unspecified Malignant tumour, unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Continued ->

Table 13: Continued.

Table 13: Continued.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Histological type Histologic type | Total All sites | Primary site (ICD code) Primary site (ICD code) | | | | | | | | | | | | | | | | | |
| C00-C80 | C63 | C64 | C65 | C66 | C67 | C68 | C69 | C70 | C71 | C72 | C73 | C74 | C75 | C76 | C77 | C78 | C79 | C80 |
| All types | 6005 | 2 | 88 | 11 | 4 | 112 | 3 | 4 | 2 | 130 | 4 | 226 | 5 | 1 | 3 | 29 | 6 | 5 | 30 |
| Small cell sarcoma / Small cell carcinoma | 117 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-small cell carcinoma Non-small cell carcinoma | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Squamous cell carcinoma Squamous cell carcinoma | 866 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 23 | 1 | 0 | 3 |
| Basal cell carcinoma / Basal cell carcinoma | 191 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Transitional cell carcinoma Transitional cell carcinoma | 122 | 0 | 0 | 11 | 4 | 105 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adenocarcinoma / Adenocarcinoma | 3546 | 0 | 86 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 221 | 1 | 0 | 1 | 2 | 4 | 2 | 13 |
| Other specified carcinomas Other specified carcinomas | 90 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Carcinoma, unspecified | 43 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Malignant thymoma / Malignant thymoma | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant paraganglioma/pheochromocytoma Malignant paraganglioma/pheochromocytoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant melanoma / Malignant melanoma | 524 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 6 |
| Fibrosarcoma / Fibrosarcoma | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrohistiocytic sarcoma / Fibrohistiocytic sarcoma | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liposarcoma / Liposarcoma | 22 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leiomyosarcoma / Leiomyosarcoma | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rhabdomyosarcoma / Rhabdomyosarcoma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Synovial sarcoma / Synovial sarcoma | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Angiosarcoma / Angiosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kaposi sarcoma / Kaposi sarcoma | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Osteosarcoma / Osteosarcoma | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chondrosarcoma / Chondrosarcoma | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ewing sarcoma/PNET / Ewing sarcoma/PNET | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified sarcomas Other specified sarcomas | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sarkom, neopredeljen / Sarcoma, unspecified | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Complex mixed and stromal malignant tumours Malignant complex mixed and stromal tumours | 43 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibroepithelial malignant tumours Malignant fibroepithelial tumours | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant mesothelioma Malignant mesothelioma | 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gonadal stromal tumours Malignant gonadal stromal tumours | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dysgerminoma and seminoma Dysgerminoma and seminoma | 86 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other malignant germ cell tumours Other malignant germ cell tumours | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant trophoblastic tumours Malignant trophoblastic tumours | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant gliomas / Malignant gliomas | 134 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant neuroepithelial tumours Malignant neuroepithelial tumours | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant meningioma Malignant meningioma | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malignant nerve sheath tumours Malignant nerve sheath tumours | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other specified malignant tumours Other specified malignant tumours | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Malignant tumour, unspecified Malignant tumour, unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Table 14: Incidence ofnon-Hodgkin's lymphomas (NHL) by site, OI Ljubljana 2022 Table 14: Incidence of non-Hodgkin's lymphomas (NHL) by site, OI Ljubljana 2022.

|  |  |  |
| --- | --- | --- |
| ICD-8 Code ICD-8 Code | Primary site Primary site | All ages All ages |
|  | All non-Hodgkin lymphomas  All non-Hodgkin's lymphomas | 399 |
| 142 | Salivary glands | 2 |
| 145 | Mouth, other Mouth, other | 2 |
| 146 | Oropharynx Oropharynx | 4 |
| 151 | Stomach Stomach | 13 |
| 152 | Small intestine Small intestine | 4 |
| 153 | Colon Colon | 2 |
| 154 | Rectum Rectum | 1 |
| 158 | Retro-, peritoneum Retro-, peritoneum | 1 |
| 160 | Nose, nasal cavities, other Nose, nasal cavities, other | 4 |
| 162 | Trachea, bronchus, lung Trachea, bronchus, lung | 8 |
| 170 | Bone Bone | 5 |
| 171 | Soft tissue Soft tissue | 2 |
| 173 | Skin, other malignancies Skin, other malignancies | 14 |
| 174 | Breastfeeding Breast | 1 |
| 186 | Modo Testis | 1 |
| 189 | Kidney, ureter, other Kindey, ureter, other | 1 |
| 190 | Eye Eye | 7 |
| 191 | Brain Brain | 14 |
| 192 | Nervous system, other Nervous system, other | 2 |
| 193 | Thyroid Thyroid | 2 |
| 202 | Lymph nodes Lymph nodes | 309 |

Table 15: Cancer incidenceby stage, OI Ljubljana 2022 Table 15: Cancer incidence by stage, OI Ljubljana 2022.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ICD ICB code  code | Primary site Primary site | Number of new cases Number of new cases | Stadij / Stage | | | | | | | |
| Limited Localised | | Extended Regional | | Distant | | Unknown Unknown | |
| Number Number | %\* | Number Number | %\* | Number Number | %\* | Number Number | %\* |
| C00- C80 | Males and females  All locations / All sites Men / Males Women / Females | 6105 | 2664 | 43,6 | 2156 | 35,3 | 1242 | 20,3 | 43 | 0,7 |
| 3079 | 1257 | 40,8 | 1155 | 37,5 | 644 | 20,9 | 23 | 0,7 |
| 3026 | 1407 | 46,5 | 1001 | 33,1 | 598 | 19,8 | 20 | 0,7 |
| C00 | Lip / Lip | 13 | 12 | 92,3 | 1 | 7,7 | 0 | 0,0 | 0 | 0,0 |
| C01 | Bazazika / Base of tongue | 21 | 2 | 9,5 | 18 | 85,7 | 1 | 4,8 | 0 | 0,0 |
| C02 | Jezik, drugi deli / Tongue, other & unspecified parts | 24 | 5 | 20,8 | 19 | 79,2 | 0 | 0,0 | 0 | 0,0 |
| C03 | Wood / Gum | 8 | 1 | 12,5 | 7 | 87,5 | 0 | 0,0 | 0 | 0,0 |
| C04 | Floor of mouth | 29 | 9 | 31,0 | 18 | 62,1 | 2 | 6,9 | 0 | 0,0 |
| C05 | Or / Palate | 15 | 3 | 20,0 | 12 | 80,0 | 0 | 0,0 | 0 | 0,0 |
| C06 | Mouth, other & unspecified parts | 13 | 2 | 15,4 | 11 | 84,6 | 0 | 0,0 | 0 | 0,0 |
| C07 | Parotid gland / Parotid gland | 13 | 3 | 23,1 | 7 | 53,8 | 3 | 23,1 | 0 | 0,0 |
| C08 | Other & unspecified major salivary glands Other & unspecified major salivary glands | 1 | 1 | - | 0 | - | 0 | - | 0 | - |
| C09 | Tonzila / Tonsil | 66 | 5 | 7,6 | 58 | 87,9 | 3 | 4,5 | 0 | 0,0 |
| C10 | Oropharynx / Oropharynx | 29 | 2 | 6,9 | 25 | 86,2 | 2 | 6,9 | 0 | 0,0 |
| C11 | Nasopharynx / Nasopharynx | 10 | 0 | 0,0 | 10 | 100,0 | 0 | 0,0 | 0 | 0,0 |
| C12 | Pyriform sinus / Pyriform sinus | 22 | 0 | 0,0 | 22 | 100,0 | 0 | 0,0 | 0 | 0,0 |
| C13 | Hypopharynx / Hypopharynx | 14 | 4 | 28,6 | 8 | 57,1 | 2 | 14,3 | 0 | 0,0 |
| C14 | Other and ill-defined sites in the lip, oral cavity and pharynx Other and ill-defined sites in the lip, oral cavity and pharynx | 0 | 0 | - | 0 | - | 0 | - | 0 | - |
| C15 | Esophagus / Oesophagus | 49 | 6 | 12,2 | 25 | 51,0 | 18 | 36,7 | 0 | 0,0 |
| C16 | Stomach / Stomach | 126 | 14 | 11,1 | 50 | 39,7 | 62 | 49,2 | 0 | 0,0 |
| C17 | Small intestine / Small intestine | 24 | 5 | 20,8 | 11 | 45,8 | 8 | 33,3 | 0 | 0,0 |
| C18 | Large intestine / Colon | 248 | 26 | 10,5 | 137 | 55,2 | 85 | 34,3 | 0 | 0,0 |
| C19 | Rectosigmoid junction | 29 | 0 | 0,0 | 20 | 69,0 | 9 | 31,0 | 0 | 0,0 |
| C20 | Rectum / Rectum | 222 | 23 | 10,4 | 151 | 68,0 | 47 | 21,2 | 1 | 0,5 |
| C21 | Anus and anal canal | 19 | 7 | 36,8 | 10 | 52,6 | 1 | 5,3 | 1 | 5,3 |
| C22 | Liver and intrahepatic bile ducts | 51 | 22 | 43,1 | 17 | 33,3 | 12 | 23,5 | 0 | 0,0 |
| C23 | Gallbladder / Gallbladder | 7 | 0 | 0,0 | 3 | 42,9 | 4 | 57,1 | 0 | 0,0 |
| C24 | Billiary tract, other and unspecified parts | 33 | 8 | 24,2 | 18 | 54,5 | 7 | 21,2 | 0 | 0,0 |
| C25 | Pancreas / Pancreas | 132 | 8 | 6,1 | 53 | 40,2 | 71 | 53,8 | 0 | 0,0 |
| C26 | Other and ill-defined sites in digestive organs Other and ill-defined digestive organs | 3 | 1 | - | 0 | - | 2 | - | 0 | - |
| C30 | Nasal cavity and middle ear | 19 | 5 | 26,3 | 13 | 68,4 | 0 | 0,0 | 1 | 5,3 |
| C31 | Obnosni sinusi / Accessory sinuses | 9 | 1 | 11,1 | 8 | 88,9 | 0 | 0,0 | 0 | 0,0 |
| C32 | Larynx / Larynx | 75 | 41 | 54,7 | 33 | 44,0 | 1 | 1,3 | 0 | 0,0 |
| C33 | Sapnik / Trachea | 1 | 1 | - | 0 | - | 0 | - | 0 | - |
| C34 | Sapnica and lung / Bronchus and lung | 799 | 142 | 17,8 | 268 | 33,5 | 389 | 48,7 | 0 | 0,0 |
| C37 | Timus / Thymus | 6 | 5 | 83,3 | 0 | 0,0 | 1 | 16,7 | 0 | 0,0 |
| C38 | Heart, mediastinum, pleura / Heart, mediastinum, pleura | 1 | 0 | - | 0 | - | 1 | - | 0 | - |
| C39 | Other and poorly defined sites in the respiratory tract and thoracic organs  Other and ill-defined sites in the respiratory system and intrathoracic organs | 0 | 0 | - | 0 | - | 0 | - | 0 | - |
| C40 | Bone and articular cartilage of limbs | 8 | 1 | 12,5 | 2 | 25,0 | 5 | 62,5 | 0 | 0,0 |
| C41 | Bone, articular cartilage, elsewhere  Bone and articular cartilage of other and unspecified parts | 15 | 6 | 40,0 | 7 | 46,7 | 2 | 13,3 | 0 | 0,0 |
| C43 | Malignant melanoma of the skin / Malignant melanoma of skin | 505 | 343 | 67,9 | 144 | 28,5 | 15 | 3,0 | 3 | 0,6 |
| C44 | Other malignant neoplasms of the skin / Skin, excl. melanoma | 371 | 309 | 83,3 | 59 | 15,9 | 1 | 0,3 | 2 | 0,5 |
| C45 | Mesothelioma / Mesothelioma | 26 | 9 | 34,6 | 12 | 46,2 | 4 | 15,4 | 1 | 3,8 |
| C46 | Kaposi's sarcoma / Kaposi's sarcoma | 1 | 1 | - | 0 | - | 0 | - | 0 | - |
| C47 | Peripheral nerves and autonomic nervous system  Peripheral nerves and autonomic nervous system | 2 | 0 | - | 1 | - | 0 | - | 1 | - |

Continued -> Continued ->

Table 15: Continued.

Table 15: Continued.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ICD ICB code  code | Primary site Primary site | Number of new cases Number of new cases | Stadij / Stage | | | | | | | |
| Limited Localised | | Extended Regional | | Distant | | Unknown Unknown | |
| Number Number | %\* | Number Number | %\* | Number Number | %\* | Number Number | %\* |
| C48 | Peritoneum and retroperitoneum / Retroperitoneum and peritoneum | 16 | 2 | 12,5 | 10 | 62,5 | 4 | 25,0 | 0 | 0,0 |
| C49 | Other connective and soft tissue | 50 | 15 | 30,0 | 28 | 56,0 | 7 | 14,0 | 0 | 0,0 |
| C50 | Breastfeeding / Breast | 1079 | 648 | 60,1 | 346 | 32,1 | 84 | 7,8 | 1 | 0,1 |
| C51 | Female external genitalia / Vulva | 34 | 18 | 52,9 | 13 | 38,2 | 3 | 8,8 | 0 | 0,0 |
| C52 | Scissors / Vagina | 6 | 3 | 50,0 | 3 | 50,0 | 0 | 0,0 | 0 | 0,0 |
| C53 | Cervical cervix / Cervix uteri | 60 | 12 | 20,0 | 33 | 55,0 | 15 | 25,0 | 0 | 0,0 |
| C54 | Uterine body / Corpus uteri | 190 | 96 | 50,5 | 77 | 40,5 | 16 | 8,4 | 1 | 0,5 |
| C55 | Uterus, unspecified | 4 | 2 | - | 0 | - | 2 | - | 0 | - |
| C56 | Ovary / Ovary | 105 | 10 | 9,5 | 13 | 12,4 | 82 | 78,1 | 0 | 0,0 |
| C57 | Other and unspecified female genital organs  Other and unspecified parts of female genital organs | 38 | 3 | 7,9 | 7 | 18,4 | 28 | 73,7 | 0 | 0,0 |
| C58 | Cot / Placenta | 0 | 0 | - | 0 | - | 0 | - | 0 | - |
| C60 | Penis / Penis | 4 | 1 | - | 3 | - | 0 | - | 0 | - |
| C61 | Prostate / Prostate | 647 | 323 | 49,9 | 212 | 32,8 | 108 | 16,7 | 4 | 0,6 |
| C62 | Modo / Testis | 130 | 93 | 71,5 | 24 | 18,5 | 13 | 10,0 | 0 | 0,0 |
| C63 | Other and unspecified male genital organs Other and unspecified male genital organs | 2 | 2 | - | 0 | - | 0 | - | 0 | - |
| C64 | Kidney, excl. renal pelvis | 93 | 27 | 29,0 | 29 | 31,2 | 37 | 39,8 | 0 | 0,0 |
| C65 | Renal bladder / Renal pelvis | 11 | 0 | 0,0 | 7 | 63,6 | 4 | 36,4 | 0 | 0,0 |
| C66 | Ureter / Ureter | 4 | 1 | - | 3 | - | 0 | - | 0 | - |
| C67 | Urinary bladder / Bladder | 112 | 55 | 49,1 | 41 | 36,6 | 16 | 14,3 | 0 | 0,0 |
| C68 | Other and unspecified urinary organs Other and unspecified urinary organs | 3 | 0 | - | 1 | - | 2 | - | 0 | - |
| C69 | Eye and adnexa | 5 | 3 | 60,0 | 2 | 40,0 | 0 | 0,0 | 0 | 0,0 |
| C70 | Meninge / Meninges | 2 | 2 | - | 0 | - | 0 | - | 0 | - |
| C71 | Brain / Brain | 133 | 132 | 99,2 | 0 | 0,0 | 1 | 0,8 | 0 | 0,0 |
| C72 | Spinal cord, cranial nerves and other parts of the central nervous system (CNS)  Spinal cord, cranial nerves and other parts of  central nervous system (CNS) | 4 | 4 | - | 0 | - | 0 | - | 0 | - |
| C73 | Thyroid gland / Thyroid gland | 225 | 177 | 78,7 | 43 | 19,1 | 5 | 2,2 | 0 | 0,0 |
| C74 | Adrenal gland / Adrenal gland | 6 | 1 | 16,7 | 1 | 16,7 | 4 | 66,7 | 0 | 0,0 |
| C75 | Other endocrine glands and related structures Other endocrine glands and related structures | 1 | 1 | - | 0 | - | 0 | - | 0 | - |
| C76 | Other and ill-defined sites | 5 | 0 | 0,0 | 2 | 40,0 | 3 | 60,0 | 0 | 0,0 |
| C77 | Metastasis and unspecified malignant neoplasm of lymph nodes Metastasis and unspecified malignant neoplasm of lymph nodes | 31 | 0 | 0,0 | 0 | 0,0 | 4 | 12,9 | 27 | 87,1 |
| C78 | Respiratory and gastrointestinal metastases  Metastases of respiratory and digestive organs | 6 | 0 | 0,0 | 0 | 0,0 | 6 | 100,0 | 0 | 0,0 |
| C79 | Metastases of other sites | 7 | 0 | 0,0 | 0 | 0,0 | 7 | 100,0 | 0 | 0,0 |
| C80 | Malignant neoplasm without specification of site Malignant neoplasm without specification of site | 33 | 0 | 0,0 | 0 | 0,0 | 33 | 100,0 | 0 | 0,0 |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ICD ICB code  code | Primary site Primary site | Number of new cases Number of new cases | Stadij / Stage | | | | | | | |
| I | | II | | III + IV | | Neznan / Unknown | |
| Number Number | %\* | Number Number | %\* | Number Number | %\* | Number Number | %\* |
| C81 | Hodgkin's lymphoma / Hodgkin's lymphoma | 57 | 6 | 10,5 | 23 | 40,4 | 27 | 47,4 | 1 | 1,8 |
| C82 | Follicular non-Hodgkin's lymphoma Follicular non-Hodgkin's lymphoma | 123 | 39 | 31,7 | 14 | 11,4 | 68 | 55,3 | 2 | 1,6 |
| C83 | Diffuse non-Hodgkin's lymphoma / Ditfuse non-Hodgkin's lymphoma | 238 | 47 | 19,7 | 27 | 11,3 | 163 | 68,5 | 1 | 0,4 |
| C84 | T-cell lymphomas and cutaneous T-cell lymphomas Peripheral and cutaneous T-cell lymphomas | 34 | 9 | 26,5 | 2 | 5,9 | 21 | 61,8 | 2 | 5,9 |
| C85 | Other and unspecified types of non-Hodgkin's lymphoma Other and unspecified types of non-Hodgkin's lymphoma | 4 | 1 | - | 1 | - | 1 | - | 1 | - |

\*Percentages are not calculated if the number of new cases is below 5.

Treatment

*Treatment*

Table 16a: Numberand proportions of surgeries, systemic treatments and radiation treatments by location for patients admitted for the first time to the Ljubljana ICU in 2022.

Table 16a: Numberand proportions of surgeries, systemic treatments and radiotherapy by site for patients first admitted to the OI Ljubljana in 2022.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ICD-10 code ICD-10 code | Primary site Primary site | Number of new cases Number of new cases | Number treated in any way  Number of all treated | | Number of treated by surgery\* Number of treated by surgery\* | | Number of treated by systemic therapy Number of treated by systemic therapy | | Number of treated Number of treated by radiotherapy | |
| Number Number | % | Number Number | % | Number Number | % | Number Number | % |
| C00-C96 | All locations / All sites | 6659 | 5484 | 82,4 | 1774 | 26,6 | 3104 | 46,6 | 3490 | 52,4 |
| C00-C14 | Usta in žrelo / Mouth and pharynx | 278 | 258 | 92,8 | 0 | 0,0 | 29 | 10,4 | 251 | 90,3 |
| C15 | Esophagus / Oesophagus | 49 | 37 | 75,5 | 0 | 0,0 | 10 | 20,4 | 34 | 69,4 |
| C16 | Stomach / Stomach | 126 | 96 | 76,2 | 21 | 16,7 | 73 | 57,9 | 29 | 23,0 |
| C18 | Large intestine / Colon | 248 | 196 | 79,0 | 71 | 28,6 | 140 | 56,5 | 12 | 4,8 |
| C19-C20 | Rectum and rectosigmoid junction Rectum and rectosigmoid junction | 251 | 231 | 92,0 | 73 | 29,1 | 135 | 53,8 | 169 | 67,3 |
| C22 | Liver and intrahepatic bile ducts Liver and intrahepatic bile ducts | 51 | 16 | 31,4 | 0 | 0,0 | 6 | 11,8 | 10 | 19,6 |
| C23-C24 | Gallbladder and biliary tract Gallbladder and biliary tract | 40 | 14 | 35,0 | 0 | 0,0 | 10 | 25,0 | 4 | 10,0 |
| C25 | Pancreas / Pancreas | 132 | 47 | 35,6 | 0 | 0,0 | 36 | 27,3 | 14 | 10,6 |
| C32 | Larynx / Larynx | 75 | 73 | 97,3 | 0 | 0,0 | 2 | 2,7 | 72 | 96,0 |
| C33-C34 | Trachea, bronchus and lung | 800 | 685 | 85,6 | 2 | 0,3 | 264 | 33,0 | 607 | 75,9 |
| C43 | Malignant melanoma of the skin Malignant melanoma of the skin | 505 | 375 | 74,3 | 359 | 71,1 | 54 | 10,7 | 24 | 4,8 |
| C44 | Other malignant neoplasms of the skin Skin, excl. melanoma | 371 | 284 | 76,5 | 49 | 13,2 | 12 | 3,2 | 235 | 63,3 |
| C48-C49 | Connective and soft tissue Connective and soft tissue | 66 | 56 | 84,8 | 36 | 54,5 | 11 | 16,7 | 29 | 43,9 |
| C50 | Breastfeeding / Breast | 1079 | 1040 | 96,4 | 824 | 76,4 | 895 | 82,9 | 757 | 70,2 |
| C53 | Cervical cervix / Cervix uteri | 60 | 54 | 90,0 | 3 | 5,0 | 11 | 18,3 | 52 | 86,7 |
| C54 | Uterine body / Corpus uteri | 190 | 175 | 92,1 | 58 | 30,5 | 64 | 33,7 | 141 | 74,2 |
| C56 | Ovary / Ovary | 105 | 89 | 84,8 | 34 | 32,4 | 84 | 80,0 | 2 | 1,9 |
| C61 | Prostate / Prostate | 647 | 548 | 84,7 | 3 | 0,5 | 420 | 64,9 | 423 | 65,4 |
| C62 | Modo / Testis | 130 | 77 | 59,2 | 1 | 0,8 | 75 | 57,7 | 4 | 3,1 |
| C64-C65 | Kidney with renal pelvis Kidney with renal pelvis | 104 | 78 | 75,0 | 4 | 3,8 | 57 | 54,8 | 33 | 31,7 |
| C67 | Urinary bladder / Bladder | 112 | 74 | 66,1 | 0 | 0,0 | 53 | 47,3 | 34 | 30,4 |
| C70-C72 | Central and autonomic nervous system Central and autonomic nervous system | 139 | 119 | 85,6 | 0 | 0,0 | 77 | 55,4 | 105 | 75,5 |
| C73 | Thyroid gland / Thyroid gland | 225 | 210 | 93,3 | 186 | 82,7 | 185 | 82,2 | 122 | 54,2 |
| C81 | Hodgkin's lymphoma Hodgkin's lymphoma | 57 | 53 | 93,0 | 0 | 0,0 | 49 | 86,0 | 24 | 42,1 |
| C82-C85 | Non-Hodgkin's lymphomas Non-Hodgkin's lymphomas | 399 | 317 | 79,4 | 7 | 1,8 | 239 | 59,9 | 137 | 34,3 |
| C90 | Diffuse plasmacytoma and malignant neoplasms of the plasmacytes  Multiple myeloma and malignant plasma cell neoplasms | 37 | 34 | 91,9 | 0 | 0,0 | 2 | 5,4 | 34 | 91,9 |
| C91-C95 | Leukaemias / Leukaemias | 54 | 13 | 24,1 | 0 | 0,0 | 8 | 14,8 | 5 | 9,3 |
|  | Other / Others | 329 | 235 | 71,4 | 43 | 13,1 | 103 | 31,3 | 127 | 38,6 |

\*Number of curative and palliative surgical interventions. / Number of curative and palliative surgeries.

Table 16b: Number and proportions of surgeries, systemic treatments and radiation treatments by location in the first treatment at the Ljubljana ICU for patients admitted for the first time in 2022.

Table 16b: Number and proportions of surgeries, systemic treatments and radiotherapies by site

as part of the first treatment at the OI Ljubljana for patients admitted for the first time in 2022.


|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ICD-10 code ICD-10 code | Primary site Primary site | Number of new cases Number of new cases | Number treated in any way  Number of all treated | | Number of treated by surgery\* Number of treated by surgery\* | | Number of treated by systemic therapy Number of treated by systemic therapy | | Number of treated Number of treated by radiotherapy | |
| Number Number | % | Number Number | % | Number Number | % | Number Number | % |
| C00-C96 | All locations / All sites | 6659 | 4825 | 72,5 | 1742 | 26,2 | 2804 | 42,1 | 2974 | 44,7 |
| C00-C14 | Usta in žrelo / Mouth and pharynx | 278 | 247 | 88,8 | 0 | 0,0 | 23 | 8,3 | 241 | 86,7 |
| C15 | Esophagus / Oesophagus | 49 | 33 | 67,3 | 0 | 0,0 | 8 | 16,3 | 30 | 61,2 |
| C16 | Stomach / Stomach | 126 | 89 | 70,6 | 21 | 16,7 | 69 | 54,8 | 26 | 20,6 |
| C18 | Large intestine / Colon | 248 | 176 | 71,0 | 67 | 27,0 | 131 | 52,8 | 4 | 1,6 |
| C19-C20 | Rectum and rectosigmoid junction Rectum and rectosigmoid junction | 251 | 216 | 86,1 | 68 | 27,1 | 129 | 51,4 | 164 | 65,3 |
| C22 | Liver and intrahepatic bile ducts Liver and intrahepatic bile ducts | 51 | 8 | 15,7 | 0 | 0,0 | 5 | 9,8 | 3 | 5,9 |
| C23-C24 | Gallbladder and biliary tract Gallbladder and biliary tract | 40 | 11 | 27,5 | 0 | 0,0 | 10 | 25,0 | 1 | 2,5 |
| C25 | Pancreas / Pancreas | 132 | 42 | 31,8 | 0 | 0,0 | 35 | 26,5 | 10 | 7,6 |
| C32 | Larynx / Larynx | 75 | 70 | 93,3 | 0 | 0,0 | 2 | 2,7 | 69 | 92,0 |
| C33-C34 | Trachea, bronchus and lung | 800 | 582 | 72,8 | 2 | 0,3 | 244 | 30,5 | 510 | 63,8 |
| C43 | Malignant melanoma of the skin Malignant melanoma of the skin | 505 | 368 | 72,9 | 355 | 70,3 | 53 | 10,5 | 22 | 4,4 |
| C44 | Other malignant neoplasms of the skin Skin, excl. melanoma | 371 | 179 | 48,2 | 38 | 10,2 | 8 | 2,2 | 139 | 37,5 |
| C48-C49 | Connective and soft tissue Connective and soft tissue | 66 | 53 | 80,3 | 36 | 54,5 | 10 | 15,2 | 25 | 37,9 |
| C50 | Breastfeeding / Breast | 1079 | 1017 | 94,3 | 820 | 76,0 | 882 | 81,7 | 738 | 68,4 |
| C53 | Cervical cervix / Cervix uteri | 60 | 52 | 86,7 | 3 | 5,0 | 11 | 18,3 | 50 | 83,3 |
| C54 | Uterine body / Corpus uteri | 190 | 168 | 88,4 | 56 | 29,5 | 59 | 31,1 | 137 | 72,1 |
| C56 | Ovary / Ovary | 105 | 86 | 81,9 | 34 | 32,4 | 82 | 78,1 | 1 | 1,0 |
| C61 | Prostate / Prostate | 647 | 323 | 49,9 | 3 | 0,5 | 248 | 38,3 | 246 | 38,0 |
| C62 | Modo / Testis | 130 | 73 | 56,2 | 1 | 0,8 | 71 | 54,6 | 4 | 3,1 |
| C64-C65 | Kidney with renal pelvis Kidney with renal pelvis | 104 | 46 | 44,2 | 4 | 3,8 | 35 | 33,7 | 16 | 15,4 |
| C67 | Urinary bladder / Bladder | 112 | 52 | 46,4 | 0 | 0,0 | 36 | 32,1 | 25 | 22,3 |
| C70-C72 | Central and autonomic nervous system Central and autonomic nervous system | 139 | 114 | 82,0 | 0 | 0,0 | 76 | 54,7 | 101 | 72,7 |
| C73 | Thyroid gland / Thyroid gland | 225 | 209 | 92,9 | 185 | 82,2 | 185 | 82,2 | 122 | 54,2 |
| C81 | Hodgkin's lymphoma Hodgkin's lymphoma | 57 | 53 | 93,0 | 0 | 0,0 | 49 | 86,0 | 24 | 42,1 |
| C82-C85 | Non-Hodgkin's lymphomas Non-Hodgkin's lymphomas | 399 | 309 | 77,4 | 6 | 1,5 | 237 | 59,4 | 127 | 31,8 |
| C90 | Diffuse plasmacytoma and malignant neoplasms of the plasmacytes  Multiple myeloma and malignant plasma cell neoplasms | 37 | 20 | 54,1 | 0 | 0,0 | 2 | 5,4 | 20 | 54,1 |
| C91-C95 | Leukaemias / Leukaemias | 54 | 13 | 24,1 | 0 | 0,0 | 8 | 14,8 | 5 | 9,3 |
|  | Other / Others | 329 | 216 | 65,7 | 43 | 13,1 | 96 | 29,2 | 114 | 34,7 |

\*Number of curative and palliative surgical interventions. / Number of curative and palliative surgeries.

38

*Hospital registry of the Ljubljana General Hospital*







BR REPORT No 9Ljubljana , December 2023eISSN 2591-1295